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Abnormal mRNA splicing can disrupt gene function and influence the course of disease. 
Analysis of abnormal splicing is an important part of determining whether a particular 
genetic variant found in the population is pathogenic or not. However, to correctly 
identify abnormal splicing, we must first understand what is normal. This project 
assessed the isoforms of the genes BRCA1 and BARD1, which are particularly relevant 
to the onset of breast cancer. 
BRCA1 is a tumour suppressor gene implicated in breast cancer onset. BARD1 codes for 
a protein that interacts with BRCA1 and produces a smaller mRNA transcript. Normal 
exon skipping events have been identified for both BRCA1 and BARD1, however, current 
methods are unable to reliably identify full transcripts. This has resulted in knowledge 
of individual exon skipping events but often does not tell us whether multiple events 
occur in the same transcript. The MinION nanopore sequencer (Oxford Nanopore 
Technologies), uses a nanopore to produce long-read, single molecule sequences. This 
has great potential for identifying multiple long isoforms, which is not practical using 
current technologies. The aim of this project was to examine the ability of the MinION 
to identify mRNA splicing patterns of transcripts derived from BRCA1 and BARD1.  
All mRNA from a normal lymphoblastoid cell line was converted to cDNA and targeted 
genes of interest were amplified by polymerase chain reaction (PCR). All potential 
isoforms generated from BRCA1 and BARD1 were then pooled and analysed using the 
MinION sequencer. After trialling many different analysis methods, the read data was 
analysed using the BLAST-like Alignment Tool (BLAT) with two outputs, a tabular and 
a graphical format. The tabular format grouped reads into potential isoforms, while the 
graphical format allowed visualisation of these isoforms and identified the exon/intron 
boundaries. Using both these formats 34 BRCA1 isoforms and 39 BARD1 isoforms were 
identified, 24 and 17 of which were potential novel isoforms respectively. Two of these 
novel isoforms from the BRCA1 dataset (Δ10-17 and Δ11q21) were further verified 
using Sanger sequencing.  
This was a proof of principle research project that demonstrated the potential use of the 
MinION nanopore sequencer for successful characterisation of multiple mRNA 
isoforms. This research has successfully identified a number of novel isoforms from the 
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 Chapter 1: Introduction  
1.1 Overview 
An important aspect of understanding the genetic basis of many diseases is the 
underlying genetic variation that contributes to the disease phenotype. In cancer this is 
particularly important due to the nature of its development in the human body. Genetic 
variation can contribute greatly to the differential expression of mRNA alternative 
splicing patterns (splice isoforms), resulting in variations in protein expression. This 
can have vastly varying effects on cell phenotype, and in some cases can contribute to 
disease development. Currently, the most popular methods of analysing alternative 
splicing can only detect individual or adjacent exon inclusion/exclusion, and only in 
very small genes has it been possible to look easily at an entire transcript. Long-read 
sequencing devices such as the MinION nanopore sequencer, developed by Oxford 
Nanopore Technologies (ONT), have the potential to read through an entire transcript 
of a typical gene. The BRCA1 gene associated with breast cancer has been very well 
studied and is currently used in clinical decision making. It has multiple splice isoforms, 
which have yet to be fully characterised because of technological limitations. The 
BARD1 protein interacts with BRCA1 and is important for the role BRCA1 has in DNA 
repair [1]. BARD1 also has many splice isoforms. The isoforms of both BRCA1 and BARD1 
have a pathological significance in the development and progression of breast and other 
cancers. This research aimed to characterise full length transcripts, and therefore splice 
isoforms, of these two breast cancer associated genes using the MinION nanopore 
sequencer. 
1.2 BRCA1 and BARD1 
The gene BRCA1 (breast cancer susceptibility gene 1) is a well-known tumour 
suppressor discovered in 1994 [2] and has a wide variety of cellular functions [3, 4]. 
BARD1 (BRCA1-associated ring domain 1) was discovered in 1996 [5] and is another 
tumour suppressor, not quite so well known as its partner BRCA1 but arguably just as 
important. The complex formed by the resulting two proteins has ubiquitin ligase 
activity [6], and cellular functions involving both BRCA1 and BARD1 include DNA repair 
[7, 8], cell cycle progression by means of centrosome regulation [9, 10], and general 
genetic stability [1, 8, 10]. BARD1 has an important role in controlling BRCA1 function 
and localisation [1, 8, 11, 12], and is independently involved with inhibition of mRNA 
maturation [13, 14], contact inhibition of cell growth [15], apoptosis by means of p53 
stability [16], and repression of cellular oncogenic features [15].  
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1.2.1 Gene structure 
BRCA1 is located on chromosome 17 (17q21), and is 81 kilobases (kb) long [17]. BRCA1 
has 23 exons1 with exon 11 being one of the longest coding exons in the genome (3kb) 
[18, 19]. The full length transcript is 7.2 kb [20]. BARD1 is located on chromosome 2 
(2q35), and is 84kb long [17]. It has 11 exons, and the length of the full length transcript 
is 2.6 kb [20]. Figure 1.1 shows a schematic of these genes with functional areas 
annotated. 
BRCA1 has three main domains that have been identified with specific functions (Figure 
1.1a). At the N-terminal of the protein, encoded by exons 2 to 7, is the RING (Really 
Interesting New Gene) domain, a finger-like domain essential for BARD1 binding [3, 5, 
21]. In the middle lies the region encoded by exons 11-13 that contain binding sites for 
γ-tubulin [22, 23] and many proteins involved in cellular pathways associated with 
cancer [3, 24]. This region also contains nuclear localisation signals (NLS) [25, 26] and 
nuclear export signals (NES) [27, 28]. At the C-terminal lies the BRCT (BRCA1 C-
Terminus) domain, encoded in exons 16 to 24, a mainly phosphoprotein binding region 
that also has DNA binding function and some non-phosphoprotein interactions [29]. 
RING and BRCT domains are also present in BARD1 (Figure 1.1b), encoded by exons 1 
to 3 and exons 9 to 11 respectively [1]. BARD1 also has Ankyrin (ANK) repeats encoded 
by exons 4 to 7, which are involved with protein binding, particularly to the prominent 
tumour suppressor p53 [1]. BARD1 has fewer mutations than BRCA1, lending to the 
theory that BARD1 is of higher functional importance than BRCA1 because it has less 
tolerance for mutation [1].   
1.2.2 Cellular functions of BRCA1 and BARD1 proteins 
Ubiquitin Ligase activity: The BRCA1-BARD1 complex acts as an E3 Ubiquitin ligase, 
which catalyses Lys-6-linked polyubiquitin chains on itself (auto-ubiquitination) and on 
other proteins [6, 30]. Lys-6 linkage is not a degradation signal like more common 
ubiquitin linkages, and though some research points to it having some involvement with 
DNA repair, [30, 31]  this theory has been extrapolated from the repair functions of 
BRCA1/BARD1, and has not been explicitly proven. 
DNA damage response: The BRCA1-BARD1 complex functions in DNA damage response, 
particularly evidenced by its actions after UV radiation damage [31, 32]. BARD1 
                                                          
1 BRCA1’s exons are numbered 1 – 24 because exon 4 is no longer classified as an exon and is omitted. 
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instigates localisation to the nucleus, enabling BRCA1 to facilitate the repair of double 
stranded breaks, thereby stabilising chromatin structure [7, 11, 32].  
Cell cycle regulation: The BRCA1-BARD1 complex interacts with the tumour suppressor 
Retinoblastoma protein (RB) by means of regions encoded within BRCA1 exon 11, 
causing cell cycle arrest through promotion of RB activity [3, 33]. BRCA1 also halts cell 
cycle progression through binding to and inhibiting c-Myc, an oncogene which 
promotes transcription of a large portion of the genome [34, 35]. The complex has also 
been associated with regulation of centrosomes in a dividing cell, as division is no longer 
controlled when the BRCA1-BARD1 complex is absent or non-functional [36-39]; 
however, this fact by itself has been postulated to have nothing to do with chromosome 
instability [38]. Each protein appears to individually provoke an apoptotic response 
when localised to the cytoplasm, and a cell survival response when localised to the 
nucleus [4, 40, 41].  
Each of these cellular functions demonstrates the importance of these two genes in 
maintaining cellular integrity. The consequences of the breakdown of these processes 
can in time lead to the development and progression of a tumour, through lack of DNA 





Figure 1.1 BRCA1 (a) and BARD1 (b) exon structure and areas coding for major functional domains.  
BRCA1 exon 4 is not shown, as it is no longer classified as an exon. Nuclear localisation and export sequences are dispersed throughout each gene, usually close to the functional 
domains indicated. RING domain refers to the finger-like domain typical of protein binding regions. BRCT domain refers to a region typical of cell cycle regulatory proteins, named for 
the BRCA1 C-terminus. This original figure is not to scale. 
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1.3 Pre-mRNA processing and final mRNA structure 
Messenger RNA (mRNA) is copied from the DNA template and is translated into protein 
by the ribosome [42]. Non-coding types of RNA, such as transfer RNA (tRNA), and 
ribosomal RNA (rRNA), assist in this process by matching each mRNA codon to the 
appropriate amino acid (tRNA) and forming a crucial part of the ribosomal machinery 
(rRNA) [43-45]. Still more types of non-coding RNA include microRNA (miRNA), small 
nuclear RNA (snRNA) and many others that contribute to many biological systems [46].  
The precursor mRNA (pre-mRNA) transcript goes through many modifications before 
it is translated into a protein. Most modifications occur co-transcriptionally, while the 
strand is still being produced by RNA polymerase (RNAP) [47-52]. To prevent 
degradation a 7-methylguanosine nucleotide is added to the 5’ end (a process called 
“capping”) immediately upon exit of the beginning of the transcript from the 
polymerase, and a 3’ poly(A) tail is added to the other end once the full molecule has 
been produced [53].  Both the 5’ cap and 3’ poly(A) tail are also involved with nuclear 
export, translation, transcription termination (poly(A) tail only), and splicing out of 
introns (5’ cap only) [54-57].  
Degradation of mRNA occurs by a process called nonsense-mediated decay (NMD) [58]. 
This pathway’s main purpose is to initiate the degradation of mRNA transcripts that 
have a premature stop codon. NMD has also been identified as playing a role in the 
regulation of gene expression [58]. Inhibitors of NMD, such as cycloheximide, have been 
used to track mRNA transcript expression when variants are likely to result in mRNA 
degradation [59]. Inhibiting NMD is an important step during analysis, as transcripts 
that would normally need to be degraded by NMD may be upregulated in disease if they 
are pathogenic, and characterising these transcripts is important to further our 
understanding of disease mechanisms. 
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1.3.1 Alternative Splicing 
The structure of genes on mammalian DNA necessitates the splicing out of introns, non-
coding stretches of gene, from the mRNA transcript. This leaves only exons, the coding 
portions of the gene that remain to be translated. However, every exon is not always 
included in the final mRNA, (exon exclusion) and occasionally parts of introns have been 
found to be included in the final transcript (intron inclusion) [60, 61]. This phenomenon 
is known as alternative splicing, and it means that many mRNA isoforms can be present 
in a cell or tissue, generating different protein isoforms (Figure 1.2). Variation in factors 
that influence splicing is therefore integral to the flexibility of protein function in cells 
and tissues [53]. 
 
Figure 1.2: Alternative Splicing.  
Illustration courtesy of National Human Genome Research Institute (2016). 
https://www.genome.gov/images/edkit/bio2j_large.gif  
 
Alternative splicing is facilitated by both cis-acting factors (consensus sequences 
around splice sites within exons and introns), and trans-acting factors (splicing 
proteins) [53, 56]. Cis-acting exon splice enhancers/silencers (ESE/S) and intron splice 
enhancers/silencers (ISE/S) [53], along with the sequence of bases at the exon/intron 
boundary, influence where splicing occurs and are demonstrated in Figure 1.3. In 
particular, NAGNAG repeats at the 5’ end of an exon (acceptor site) give the option of a 
second splice site located three bases away from the initial one, i.e. after the first “NAG” 
or the second “NAG”. Sequences at the 3’ end of the exon (donor site) may also have 
characteristic motifs. Most of the proteins involved in splicing typically form a complex 
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called the spliceosome, which recognises the splice sites and enables splicing (Figure 
1.3) [42, 53, 62]. The splice site consensus sequence is recognised by small nuclear 
ribonucleoproteins (snRNPs) that compose the part of the spliceosome complex that 
recognises the sequence [51, 63]. The consensus sequence may be strong or weak, and 
as such has differing affinities for the recognition snRNPs, contributing in part to the 
decision as to which parts of the RNA transcript are spliced out [64, 65]. The complexity 
of alternative splicing, demonstrated in Table 1.1, allows for numerous possibilities for 
protein variation within and between tissues [60], and draws attention to the 
considerable impact alterations in splicing mechanisms have on cell and tissue function.  
 
 
Splicing is subject to many factors, from environmental changes like exposure to 
ultraviolet radiation [66, 67], to inherent variation in sequence and protein expression, 
to chromatin structure due to transcription coupled splicing [47, 49-51, 68-70]. The 
formation of secondary structures by the RNA strand during transcription also 
influences access of splicing factors to the consensus sequence [71, 72], and all these 
processes are subject to the speed of the RNA polymerase as it transcribes the gene. 
Studies have shown that the slower the gene is transcribed, the more likely certain 
exons will be included in the final transcript [73-77]. With so many factors contributing 
to splicing, it is extremely likely that variations in sequence causing aberrant alternative 
splicing or regulation of splicing will contribute to the development and progression of 
a significant number of cancers.  
 
Figure 1.3: Cis- and trans- acting factors involved in alternative splicing of exons.  
Green: factor that facilitates splicing, Red: factor that prevents splicing. Dashed arrows show 
where trans factors interact with cis factors. NAGNAG splice sequence on 5’ end of exon, and an 




Table 1.1: Alternative splice type identified with BRCA1 transcript analysis [60].* 
                                                          
a Diagrams modified from Colombo et al. (2014) [60].  
b NAGNAG sites are tandem exon acceptor sites that allow splicing either after the initial “NAG” or after the whole “NAGNAG” sequence. 
 
*Table continued on following page 




Cassettes Exon excluded or non-constitutive exon included 








Splice donor shifts Alternative use of NAGNAGb sites or (rarely) use 
of another site 
 
4 
Splice acceptor shifts Alternative use of acceptor sites 
 
4 
Terminal modifications Premature termination codon 
 
2 
Intronisations An internal part of an exon is spliced out 
 
2 







                                                          
a Diagrams modified from Colombo et al. (2014) [60].  
 




Multi-cassette + acceptor 
shift 




Terminal + multi-cassette Both terminal modification and multi-cassette 
event are present 
 
3 
Cassette + multi-cassette Both a single cassette event and a multi-cassette 
event are present 
 
1 
Donor shift + acceptor shift Both a donor shift and acceptor shift are present 
 
1 
Donor shift + cassette + 
multi-cassette 
Donor shift, cassette event and multi-cassette 





1.3.2 BRCA1 and BARD1 isoforms and the ENIGMA Splicing Working Group 
The ENIGMA Consortium (Evidence-based Network for the Interpretation of Germline 
Mutant Alleles) is a multinational group dedicated to the study of breast and ovarian 
cancer associated genes [78]. ENIGMA members have published numerous papers 
related to guidelines associated with identifying sequence variants and associated 
splicing changes to aid clinical classification of such variants [79-83], the identification 
of the alternative splicing of BRCA1 and BRCA2 [60, 84, 85], and compilations of variant 
and splice data [80, 81, 86]. Some of the recommendations on splicing analysis that have 
arisen from these publications include: sequencing all products, using data from at least 
10 controls, and utilising comparisons between data and reference datasets [80, 81]. 
Mini-gene assays are a popular way of determining the influence of variations in splice 
sites on alternative splicing of a particular area of a gene [18, 19, 87-89]; however, they 
are only able to functionally assay parts of the gene and not the full isoform (mini-gene 
methods of analysis are discussed in Section 1.4). This is not a viable method of 
determining exon connectivity across the whole transcript in a biological system, and at 
present, there is an inability to measure exon connectivity over longer distances, 
particularly with features like the 3kb exon 11 in BRCA1.  
Colombo et al. (2014) [60] in collaboration with the ENIGMA consortium has published 
a comprehensive study on naturally occurring BRCA1 splice variants and many other 
studies have included analysis of BARD1 isoforms [16, 90-101]. Colombo et al. identified 
63 alternative splicing events, defined by the splice junctions identified, only 28 of 
which had been previously published. Interestingly, the study found that every internal 
exon was alternatively spliced at least once, suggesting that BRCA1 does not have 
constitutive exons. This study also demonstrated the extent of transcript variation, 
demonstrated in Table 1.1 by the number of each type of BRCA1 splicing event detected. 
The authors did note that though this is the most in-depth analysis of BRCA1 alternative 
splicing events to date, they were not able to identify full length mRNA isoforms present 
(they did not perform cloning analysis), nor their level of expression. This means that 
linked splicing events (where multiple exons far apart are always spliced out together), 
that generate a particular isoform in high abundance, are uncertain in BRCA1 [60]. 
There are currently 46 published isoforms of BARD1 [16, 90-102], some of which have 
been validated by sequencing. 
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For both BRCA1 and BARD1 evidence points to full length transcripts being protective, 
and various isoforms tending to have oncogenic-like activity [16, 60, 90-96, 98, 103], 
such as BRCA1-IRIS, a product encoded by an open reading frame extending from codon 
1 to a termination point a short way into intron 11 [104-106]. The oncogenic activity is 
apparently due to the lack of functional domains encoded by particular exons that are 
spliced out, such as the RING domains, nuclear localisation and export sequences, ANK 
repeats and BRCT domains (Figure 1.1) Many of the BARD1 isoforms are missing exon 
4, which constitutes a large portion of the full length transcript but has no associated 
annotated functional regions of protein. Some more well-known isoforms of BARD1 
have been shown to have functional importance, such as BARD1β. This isoform is 
missing exons 2 and 3, which encode a RING domain, and as such is known for having a 
strong oncogenic effect when highly expressed [90, 95], mainly due to the lack of 
interaction with BRCA1. There are very few isoforms that have been characterised that 
have not been detected in normal tissue [16, 90-101]. 
Splice isoforms play an important role in the pathogenesis of diseases, especially cancer, 
and should be treated as clinically relevant. It has already been suggested that 
knowledge of splice isoforms can help develop treatments [103], and this is a key reason 
for characterising and classifying isoforms of high risk genes such as BRCA1 and BARD1. 
Sequence variation such as point mutations in regulatory regions such as enhancers and 
silencers, as well as those in splice sites themselves, play a significant role in 
determining the splicing pattern of individual genes [18, 19], and as such have 
functional and pathological significance [79, 107]. The classification of this genetic 
variation in high risk genes is therefore important in clinical decision making, as these 
variants, through their influence on splicing, can have a significant effect on disease 
development and progression [82]. Inclusion of mRNA splicing assays into the 
multifactorial risk assessment of variants is therefore essential for classifying many 
variants of unknown clinical significance in the BRCA1 gene [79]. Correctly identifying 
these pathogenic variants is essential for the clinical evaluation and risk assessment of 
a patient with breast/ovarian cancer [79, 84]. In fact, loss of function in BARD1 is 
predominantly through splicing changes, not mutation of coding sequence [82]. 
Determining the extent of naturally occurring isoforms in BRCA1 and BARD1 is essential 
to understand the pathological implications of alterations in the splicing landscape of 
these genes. Successful variant classification, however, is difficult due to the length of 
time it takes to perform sufficient functional assays on an individual variant to 
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determine its pathogenicity [108]. The consistency of annotation across research 
groups and databases needs to improve in order to provide adequate clinical care across 
all disease types [86], though ENIGMA displays expertise in this area. 
1.3.2.1 Splice event nomenclature 
Isoforms have a notation style associated with their naming which is followed in this 
report, detailed in Table 1.2.  
Table 1.2: Nomenclature of mRNA isoforms 
 
1.3.3 Other mRNA modifications 
There are other types of post-transcriptional modifications that have been found to 
occur in mammalian systems, and so there is the possibility that some might be 
applicable to BRCA1 or BARD1. Exon shuffling, including the production of circular RNA, 
is a variation of alternative splicing (and an instigator of genomic variation [109]), that 
is generally accepted to be found in human cells, particularly neurons [110, 111]. Exons 
in transcripts are not always in the order they appear on the DNA strand, indicating a 
splicing event that results in a 3' donor splice site interacting with a relatively 5' 
acceptor splice site upstream of the donor site. This can result in circular RNA, with 
intervening introns either removed or retained, but this pattern can also be found in 
linear RNA. Other methods of exon shuffling involve trans-splicing [110, 112], where 
exons from different transcripts, genes or even chromosomes are spliced together. So 
far no definitive instances of BRCA1 or BARD1 exon shuffling have been identified. 
Micro-exons have also been characterised in genes involved in neuronal and cardiac 
pathways [113-115], and have functional consequences; however, none have yet been 
found in BRCA1 or BARD1. Micro-exons are typically defined as coding regions ranging 
Symbol Meaning Example 
Δ mRNA is missing a part of the full 
length transcript 
Δ9 - Exon 9 is skipped 
Δ9,12 – exons 9 and 12 are skipped 
Δ9-12 – exons 9, 10, 11 and 12 are skipped 
11Δ3110 – 3110 bases from inside exon 11 are 
spliced out (intronisation) 
 mRNA retains a part that is not 
normally included in the full length 
transcript 
21 – retention of part of intron 21. 
Δ_p Bases are missing from the 5’ end 
(acceptor site) of an exon 
Δ5p – bases are missing from the 5’ end of exon 5. 
Could be any number of bases, identified by A or B 
etc., as described where discovered. 
Δ_q Bases are missing from the 3’ end 
(donor site) of an exon 
Δ5q – bases are missing from the 3’ end of exon 5. 
Could be any number of bases, identified by A or B 
etc., as described where discovered. 
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from 3-25 nucleotides in length, though some literature states the upper size limit as 51 
nucleotides [114-117]. Micro-exons are hard to detect using most alignment programs, 
though two groups have succeeded in developing reliable algorithms [113, 117]. Given 
this information, and the depth of high-throughput short-read mRNA sequencing data 
analysis (RNA-seq) on the genes in question, it is unlikely that BRCA1 or BARD1 contain 
undiscovered micro-exons.  
Another type of modification process is that of RNA editing [118, 119]. These include 
several types of base modifications. Adenosine and cytosine methylation involve a 
methyl group addition to these respective bases. Pseudouridine is formed when 
pseudouridine synthase “flips” uridine into an isomeric form attached to the ribose 
[120]. Pseudouridine is abundant in mammals, and has been identified as particularly 
prevalent in vitro under a stressed state [119-121]. RNA editing also includes the 
deamination of cytosine to uracil and of adenine to inosine, which occurs mainly in the 
brain [119-122]. Some RNA editing has been detected in BRCA1 transcripts in the 
intronic regions [123].  
These types of modification seem to be relatively rare in comparison to splicing 
variation. However, this could be because of a lack of reliable technology for this type of 
investigation.  
1.4 Methods of detecting exon structure 
The need for a reliable detection method of full length isoforms has grown out of the 
large body of evidence that differing isoforms from a single gene can have many 
different functions within a cell or tissue [53, 84, 111, 115, 124-126]. For example, 
transcripts of BARD1 have been identified that lack the exons encoding the RING 
domain, or the ANK repeat domains [16, 90-101]. Protein products of these transcripts 
have been identified, and are associated with poor outcomes in breast cancer patients 
[16, 90]. It is essential that there is knowledge of naturally occurring isoforms and their 
associated expression levels to allow successful clinical decision-making on the basis of 
a patient’s genetic profile. At present the studies surrounding normal BARD1 isoform 
expression have come together slowly [16, 90-101], and are less comprehensive than 
those for BRCA1, as explained in Section 1.3.2 [60].  
One of the first methods of transcript analysis was the Northern blotting technique, 
which gives a size estimation and a rough quantification; more recent methods, though, 
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are easier to use and give more accurate information. Typical methods for detecting 
transcripts presently include cloning of cDNA into bacterial plasmids and Reverse 
Transcriptase-Polymerase Chain Reaction (RT-PCR) coupled with electrophoresis or 
sequencing [80]. High-throughput RNA-sequencing (RNA-seq) is a relatively new 
method of isoform analysis that is excellent for quick and accurate identification of exon 
splicing events present in a sample. In their analysis of BRCA1 splicing events, Colombo 
et al. (2014) used all of the above analysis techniques to characterise these isoforms 
[60]. 
1.4.1 Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) 
RT-PCR is used to amplify complementary DNA (cDNA), produced from mRNA, to create 
a product requiring further analysis [127]. Reverse transcriptase converts RNA into 
cDNA, which is more stable and easier to work with. PCR is performed on the resulting 
cDNA to generate a product that is further analysed. The PCR product is initially applied 
in agarose gel electrophoresis or capillary electrophoresis for size analysis. This can 
give valuable information about the length of the transcript that can be used to support 
evidence of a particular isoform being present. Further analysis can be done by Sanger 
sequencing, in which a single band is cut out of the agarose gel, or the PCR reaction is 
purified, before sequencing. A major limitation of analysis by size is the possibility of 
two different transcripts of similar size being present in the same band; this also 
presents problems for sequencing from cut-out gel bands, as a single product is needed 
for reliable Sanger sequencing. This method was used extensively during this research 
project, coupled with agarose gel electrophoresis and both Sanger sequencing and 
MinION sequencing. 
1.4.2 Molecular Cloning 
The RT-PCR products can also be cloned into a plasmid and cultured in bacteria. The 
resulting colonies on a plate can then be picked for sequencing (typically Sanger 
sequencing), and will usually contain just one cDNA each. It is recommended to pick at 
least 40 clones off a plate to be individually sequenced [80], in order to gain a reasonably 
good representation of the isoforms present in a sample. This procedure is very 
laborious and time consuming, and also relies on chance (that colonies containing all 
the isoforms between them were picked). There may also be unforeseen bias in the 
cDNA transcripts that are successfully transformed into plasmids. 
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1.4.3 Short read RNA-Sequencing (RNA-seq) 
RNA-seq is a high throughput sequencing method that does not always require PCR 
[128]. It relies on a fragmentation method in which cDNA is produced then fragmented 
to 200-500 base pair lengths. Sequencing ranges from 30 to 400bp at a time, either using 
single-end or paired-end reads (reading a section at each end of a single molecule). The 
depth and speed of analysis is excellent, and can give reliable data on exon junctions and 
connectivity of a few exons at a time using paired-end reads. It is very accurate, and as 
such can detect sequence variations. However, the nature of short sequence reads does 
not allow for analysis of a full transcript at once. There is also bias depending on the 
type of fragmentation, either towards the transcript body or towards the 3’ end. RNA-
Seq still lacks the ability to identify splicing events between distant exons, and Wang, Z. 
et al. [128] make a point that longer reads are required for full characterisation of 
complex genomes. 
1.4.4 Other methods 
For splicing analysis, reporter mini-gene assays can be used to analyse individual genes, 
in both wild-type and pathologically mutated forms. This method was used extensively 
when characterising the splicing of exon 11 of BRCA1 [18, 19], and has also been used 
for other portions of the gene [87]. A mini-gene construct is a small section of a gene, 
usually containing several exons cloned into a vector such as a plasmid or bacterial 
artificial chromosome. This assay enables detailed analysis of splicing regions, 
regulatory elements and alternative splicing patterns of that section of the gene. This 
method does not look at splicing events across the whole gene at once.  
Synthetic long read sequencing is a process that has been developed to resolve the 
problem generated by high-throughput sequencing of multiple short sequence reads 
that are difficult to piece together [129]. The sample is essentially made so dilute when 
it is distributed across a multi-well plate that only one cDNA per well is sequenced. 
Though this eliminates the initial problem, it is a relatively inefficient, expensive and 
cumbersome technique. 
CAGE and RACE are methods for characterising 5’ ends, which are often difficult to 
characterise due to reverse transcriptase failing to extend the full length of the mRNA 
template because of mRNA length and secondary structure. CAGE is Cap Analysis Gene 
Expression [130], RACE is Rapid Amplification of cDNA Ends [131], and both focus on 
amplifying the 5’ end of transcripts (and 3’ as well in the case of RACE), using PCR and 
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restriction enzymes. These techniques are still limited by inherent PCR limitations, such 
as high GC content and polymerase processivity. 
1.4.5 Limitations of current methods 
RT-PCR combined with gel or capillary electrophoresis is not sufficient by itself to 
distinguish between transcripts of similar size. PCR also relies on primer design, which 
usually spans junctions and possible junctions to detect exon skipping, not whole 
transcripts. Sanger sequencing performed on cut-outs from an agarose gel do not give a 
good result if there is more than one transcript present of a similar size; for good Sanger 
sequencing the template DNA must be reasonably pure, i.e. one transcript per band. As 
for Sanger sequencing on cloned products, every bacterial colony needs to be sequenced 
individually. The whole process of transformation, transfection and bacterial culture is 
laborious, time consuming, and relies on chance to detect all transcripts, both at the 
transfecting stage and at selection of colonies. Sanger sequencing of cloned products is 
currently the gold standard method of isoform validation [60], and it is relatively 
expensive for the amount of data it produces. RNA-seq is excellent at detecting 
individual splice events but cannot accurately determine the whole transcript because 
of the fragmentation steps. RNA-seq methods based on short read sequencing are 
unreliable for full length isoform identification [132]. Though transcripts combining 
multiple splicing events can be statistically imputed through analysis of RT-PCR data, 
and indeed this was utilised in the BRCA1 isoform study by Colombo et al. (2014) [60], 
validation of these transcripts is still required for confirmation of these isoforms. 
1.5 Single molecule long-read DNA sequencing 
Currently, long read platforms such as the Pacific Biosciences system (PacBio) and the 
Oxford Nanopore Technologies (ONT) MinION have been employed for a small number 
of papers looking at cDNA, and even fewer on isoform detection. Neural synapse 
formation, known for its complexity, has been examined using PacBio and this study 
was successful in identifying novel transcripts of Neurexins in mice [111]. The isoforms 
of the most complicated spliced gene currently known, Dscam in Drosophila, were 
partially characterised in the MinION platform, proving that it is possible to characterise 




1.5.1 PacBio Sequencing 
The PacBio system utilises Single Molecule Real-Time (SMRT) Sequencing to generate 
long sequence reads. The current version has an average read length over 10kb and 
maximum read lengths over 60kb [133, 134]. SMRT sequencing involves tracking the 
activity of DNA polymerase as it synthesises a complementary strand with fluorescently 
labelled nucleotides. The polymerase is immobilised to the base of a tiny well that is 
smaller than the wavelength of light, allowing it to detect the nucleotide’s fluorescence 
with no background. Adapters are attached to either end of the DNA molecule to be 
sequenced which enables it to be circularised. This means the DNA polymerase can keep 
sequencing the same strand many times, generating a circular consensus sequence 
(CCS), which gives higher accuracy than a single read of the strand [133, 134]. 
Consequently, this means that the longer the DNA strand is, the less accurate the 
sequence is.  
The PacBio system has so far been used successfully for completing many bacterial 
genomes, its long reads solving some of the problems short read sequencers have not 
been able to address. The PacBio system has been used for RNA transcript analysis in 
conjunction with short sequencing reads, a process called hybrid sequencing. This 
utilises the PacBio sequence as a scaffold for aligning the more accurate short sequence 
reads, and has been successful at identifying full splice isoforms of the three neurexin 
genes [111], as well as characterising the human embryonic stem cell transcriptome 
[132]. The authors noted that their results on the transcriptome indicate that human 
gene identification is probably incomplete. 
1.5.2 MinION sequencing 
The Oxford Nanopore MinION is a nanopore sequencing device that is about the size of 
a cellphone. It works by passing DNA through a tiny pore (nanopore) set into a 
membrane with an electrical current across it. As each base passes through the pore it 
causes a unique disruption in the electrical current, generating a signal characteristic of 
each individual nucleotide. Before application to the MinION flow cell, adapters are 
ligated to the ends of the DNA strand, with a hairpin adapter linking the two strands 
together. The lead adapter guides the DNA to the nanopore, where a helicase enzyme 
separates the two strands [135]. The hairpin connects the template and complement 
strands so that after the first strand (template) has passed through the pore, the second 
strand (complement) follows. Though each strand can be analysed individually (1D 
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analysis), ideally both strands are analysed together, generating a “2D” read [136]. This 
is generally more accurate than the single sequence of either the template or the 
complement alone. The electrical signal generated is converted into a .fast5 file (HDF5 
file format) by the MinKNOW program that runs the MinION [137], and these files are 
typically sent to Metrichor over the internet, a software program based at Oxford 
Nanopore Technologies. Metrichor basecalls the sequence files and sends it back, and 
the entire process can occur within minutes. The MinION has been known to produce 
reads over 100kb in length, though an average read tends to be 10-20kb. This length is 
largely limited by fragmentation of strands during library preparation, and not by the 
device itself. 
The MinION is a relatively new sequencing technology, and has been available only 
through an early access program (the MinION Access Program, known as the MAP 
community) while in development. This means there is a limited number of publications 
related to MinION use. The MinION has been used to sequence pathogens such as the 
Ebola virus on the ground in West Africa during the Ebola outbreak [138], and also in 
sequencing bacterial pathogens such as Staphylococcus aureus and Mycobacterium 
tuberculosis in order to determine differing strains and predict antibacterial resistance 
[139]. It has been valuable in completing genomes, being able to sequence through 
repetitive regions [140]. It is particularly useful in long range connectivity within the 
genome and transcriptome, being able to sequence long haplotypes [141] and RNA 
transcripts [142, 143]. Given the broad range of applications, there is an even wider 
range of possible analysis methods. Research groups across the MAP community, 
including ONT itself, are working on software and algorithms that are suitable for long 
read sequence data produced with the unique .fast5 file format and that can handle the 
relatively high error rate of the system.  
1.5.3 Comparison of PacBio and MinION Platforms 
PacBio sequencing and MinION sequencing are based on two completely different 
methods of long-read sequencing. At present, the average read lengths of both these 
systems are more or less equivalent, but in the future this may change; the length of 
PacBio sequencing is dependent on the life of the polymerase, and can only sequence up 
to ~60kb at the time of writing, whereas theoretically the MinION has no such biological 
limitation. Due to the design of the MinION, the DNA strand can be sequenced a 
maximum of twice (the template, then the complement strands), whereas the 
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circularisation of DNA in the PacBio system allows it to be sequenced as many times as 
the lifetime of the polymerase allows. As a result, the PacBio system is typically more 
accurate than the MinION system, though the longer the read, the more the difference 
is reduced. The capital cost of the PacBio system is huge at $1million, while in 
comparison the MinION cost is extremely low (at present the cost is only for the 
consumable flow cells at ~NZ$1400 and sequencing kits). This low cost and portability 
makes the MinION a far more realistic sequencing option for smaller laboratories. 
1.6 Aims and Hypotheses 
The overall aim of this research was to examine the ability of a novel DNA sequencing 
device, the MinION, to identify mRNA splicing patterns of full length exon transcripts 
derived from the human genes BRCA1 and BARD1. The splicing patterns in BRCA1 are 
very complex and are clinically relevant, so the purpose of this project was to test 
whether the MinION could identify known and novel isoforms. BARD1 has a shorter 
transcript length than BRCA1, has less complex splicing patterns and is functionally 
related, so was chosen as a more tractable target in case BRCA1 analysis was 
unattainable. 
There were two main hypotheses: 
1. That the MinION can accurately and comprehensively generate whole transcript 
data to determine isoform structure. 
2. That MinION data will uncover novel splicing patterns in the BRCA1 transcript and 
the BARD1 transcript. 
This study explores these hypotheses by using RNA obtained from a lymphoblastoid cell 
line. The cDNA was generated from the total RNA, amplified by PCR, and run on the 
MinION. Data were analysed using specific bioinformatic and computational methods.  
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 Chapter 2: Materials and Methods  
2.1 General stocks 
2.1.1 TAE buffer (Tris/Acetic acid/EDTA) 
A stock solution of 10x TAE buffer was prepared with MPW to 1L. This was made with 
48.4g of Tris (Roche Diagnostics, Germany), 3.7g of EDTA (Ajax Finechem, 
ThermoFisher Scientific, Auckland, NZ), and 11.4mL of glacial acetic acid (Fisher 
Scientific, UK). 
2.1.2 TE buffer (Tris/EDTA) 
TE buffer was prepared by adding 1mL of 1M Tris Base (Roche Diagnostics, Germany), 
and 200µl of 0.5M EDTA (Ajax Finechem, ThermoFisher Scientific, Auckland, NZ), to a 
final volume of 100ml with MPW. The final concentrations of each were 10mM of Tris 
Base, and 1mM EDTA. 
2.2 RNA source 
RNA had already been extracted from a normal human lymphoblastoid cell line treated 
with the NMD inhibitor cycloheximide prior to the beginning of this project [102]. The 
concentration of extracted RNA was measured as 620ng/µl on a Nanodrop 8000 
spectrophotometer (Bioline, ThermoFisher Scientific). 
2.3 Primer Design 
The web program Primer3 (version 0.4.0) was used for designing all primers. The 
design parameters consisted of a minimum primer Tm of 58.5°C, optimal Tm of 60.0°C, 
and maximum Tm of 61.5°C. The minimum GC% was 20%, optimal was 50% and 
maximum was 80%.  The ideal product length range was adjusted according to the 
target region for each pair of primers, and all other parameters remained as the default 
value. Table 2.1 and Table 2.2 describes these primers and their purpose. Figure 2.1 
displays where Table 2.1 primers are positioned on the genes. Figures demonstrating 
placement of primers in Table 2.2 can be found in Appendix A. Primers (Integrated DNA 
Technologies, Singapore) were reconstituted in TE buffer to a concentration of 100µM.  
Working solutions of 10µM and 5µM (Table 2.1 primers and Table 2.2 primers 
respectively) were made from these stocks using Millipore water (MPW). Working 
solutions were stored at 4°C while stock solutions were stored at -20°C. 
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Table 2.1: Primers for cDNA synthesis, initial PCR and MinION sequencing, see Figure 2.1 for position on genes. 
                                                          
a Naming refers to the gene name, exon number, and orientation. 




Namea Primer Sequence Tm (°C)b Description 
BRCA1_1F GCGCGGGAATTACAGATAAA 68.1 BRCA1 Forward primer for full length PCR and for 5’ end confirmation. 
BRCA1_5R GAAGGCCCTTTCTTCTGGTT 69.8 BRCA1 Reverse primer for 5'end confirmation. 
BRCA1_20F GAAGAAACCACCAAGGTCCA 69.6 BRCA1 Forward primer for 3' end confirmation 
BRCA1_24pR AAGCTCATTCTTGGGGTCCT 71.0 BRCA1 Reverse primer for full length PCR and for 3’ end confirmation. 
BRCA1_24qR AGTCTTCACTGCCCTTGCAC 72.1 Synthesis of cDNA, at 3' end of exon 24, close to polyA tail.  
BARD1_1F CTCGACCGCCTGGAGAAG 70.8 BARD1 Forward primer 





Figure 2.1: Primer positions for those described in Table 2.1.  




Table 2.2: Primers for confirmation of isoforms. See Appendix A for positions on isoforms. 
                                                          
a Tm was calculated using the conditions detailed in Standard PCR for short products, using the Integrated 
DNA Technologies (IDT) tool OligoAnalyzer 3.1. https://sg.idtdna.com/calc/analyzer  
b These primers were designed if the PCR product was over 500bp in order to sequence parts of isoforms 
reliably. Otherwise the relevant PCR primer was used in sequencing reactions. 





BRCA1_9-18FJunc AGGCAAATTATTGCAGATGC 67.2 Δ10-17 
BRCA1_23RJunc ATGGAAGCCATTGTCCTCTG 69.6 Δ10-17 
BRCA1_11a-12FJunc ATCCAGAAAAGTATCAGGTGAAGC 70.4 Δ11q,19,  Δ11q,21, and  
Δ11q,14,21 
BRCA1_18-20RJunc CTCTGACTTCAAAATCATGAGAAATAG 68.3 Δ11q,19 
BRCA1_2-5FJunc GAGTGTCCCATCTGATTTTGC 68.7 Δ3,11b, and Δ3,9,10,11q 
BRCA1_11a-11cRJunc GTCAAGTCTTCCAATTCACCTGAT 70.5 Δ3,11b 
BRCA1_ins21RJunc CTCATCTGCCTGTGACCAGA 70.8 Δ11q,21 
BRCA1_20-22RJunc CATTCCAGTTGATCTTTCTGTCC 68.8 Δ11q,14,21 
BRCA1_11a-12RJunc CAGATGCTGCTTCACCTGATAC 70.3 Δ3,9,10,11q 
Flanking primers 
del10-17FFlank TCAGCTTGACACAGGTTTGG 70.1 Δ10-17 
del10-17RFlank TGGACCTTGGTGGTTTCTTC 69.6 Δ10-17 
del11qF_Flank CTCAAGGAACCAGGGATGAA 68.9 Δ11q,19,  Δ11q,21, and  
Δ11q,14,21 
del19R_Flank GTTGATCTGTGGGCATGTTG 68.9 Δ11q,19 
del3F_Flank GCGCGGGAATTACAGATAAA 68.1 Δ3,11b, and Δ3,9,10,11q 
del11bR_Flank TCACTCTCACACCCAGATGC 71 Δ3,11b 
ins21_RFlank ATGGAAGCCATTGTCCTCTG 69.6 Δ11q,21 
del21R_Flank ATGGAAGCCATTGTCCTCTG 69.6 Δ11q,14,21 
Sequencing primersb 
del11qR_Seq AGTTCAGCCATTTCCTGCTG 70.3 Δ3,9,10,11q , and  Δ11q 
del19F_Seq GGGAGAAGCCAGAATTGACA 69.5 Δ19 
del3R_Seq TCCAAACCTGTGTCAAGCTG 70.1 Δ3 
del11bF_Seq CTCAAGGAACCAGGGATGAA 68.9 Intronisation 11Δ3110 
del11q+14R_Seq TTCTGAAGACTCCCAGAGCAA 70.7 Δ11q,14 
del21F_Seq GTTTGCCAGAAAACACCACA 69.3 Δ21 
del9-11qF_Seq CAGCTTGACACAGGTTTGGA 70.1 Δ3,9,10,11q (9-11q part) 
ins21_middleFwd TCTGGTCACAGGCAGATGAG 70.8 21 
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2.4 Preparation of cDNA 
The enzyme used for cDNA synthesis was Superscript® III Reverse Transcriptase 
(Invitrogen, ThermoFisher Scientific Inc., Waltham, USA). The cDNA synthesis was 
performed according to the manufacturer’s instructions with the RNA sample described 
in Section 2.1. The final reaction volume was 20µl. All preparation was carried out in 
sterile 200µl strip tubes on ice at a pre-PCR workbench treated with RNaseZAP 
(Ambion, USA) to avoid contamination with RNase and other products. Filter pipette 
tips were used until the first heating step. Products were made up to 100µl with MPW 
and stored at -20°C. 
Three sets of primers were tested to determine which was the most effective for 
synthesising BRCA1 and BARD1 cDNA: oligo(dT), random hexamers (both sourced from 
Invitrogen, ThermoFisher Scientific Inc., Waltham, USA), and a gene specific primer for 
BRCA1. The design of the gene specific primer is described in Section 2.3, and is specific 
for the 3’ end region of BRCA1 mRNA. 
2.5 Polymerase Chain Reaction (PCR) 
All PCR reactions had a total reaction volume of 10µl, contained 3µl of the final 100µl 
cDNA solution unless otherwise stated, and were performed on an Eppendorf 
Mastercycler thermal cycler (GlobalScience, Germany). Pre-PCR preparation was 
carried out in a separate pre-PCR room to avoid risk of contamination from post-PCR 
products. Equipment and consumables (pipettes and tips, tubes and strip tubes) used 
were sterile. After 2µl was removed for gel electrophoresis, all reactions were stored at 
-20°C for Sanger and MinION sequencing. Where thermal cycling variables have been 
given a range of values in the PCR methods detailed below, a specific value is given 
separately for each result. 
2.5.1 Standard PCR for a product size <3kb 
For PCR products with length under 3kb each reaction contained 0.5µM of each forward 
and reverse primer (Integrated DNA Technologies, Singapore), 1.5mM of MgCl2, 200µM 
of each dNTP, 1x PCR reaction buffer and 0.25 units of Fisher Taq-Ti polymerase (all 
sourced from Fisher Biotec, Wembley WA, Australia). Unless otherwise stated, thermal 
cycling conditions consisted of a denaturation step of 94°C for 2 minutes, 35 cycles of 
94°C for 30 seconds, an annealing temperature between 64°C and 66°C (3-5°C below 
the Tm of primers in the reaction) for 30 seconds, an extension step at 72°C for a time 
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period according to product size (~1000bp per minute), with a final extension of 72°C 
for 5 minutes. 
2.5.2 Standard PCR for full length BRCA1 mRNA (product size 5.8kb) 
For PCR products with length over 3kb, final reactions contained 1.3M betaine (Sigma-
Aldrich, Steinheim, Germany), 1x KAPA long range buffer, 1.75mM of MgCl2 (both from 
KAPA Biosystems, Wilmington, Massachusetts), 0.5µM of each forward and reverse 
primer (BRCA1_1F and BRCA1_24pR respectively), 300µM of KAPA 10mM dNTP mix, 
and 0.5 units of KAPA Long Range HotStart (both from KAPA Biosystems, Wilmington, 
Massachusetts), added in the order given. Unless otherwise stated, thermal cycling 
conditions consisted of a denaturation step of 94°C for 4 minutes, then 35 cycles of 94°C 
for 30 seconds, a 59°C annealing temperature for 30 seconds, and an extension step at 
68°C for 12 minutes, with a final extension of 72°C for 12 minutes. 
2.5.3 Alternative PCR for full length BRCA1 mRNA 
Final reactions contained 1M betaine (Sigma-Aldrich, Steinheim, Germany), 1x KAPA 
long range buffer, 2mM of MgCl2 (both from KAPA Biosystems, Wilmington, 
Massachusetts), 0.7µM of each forward and reverse primer (BRCA1_1F and 
BRCA1_24pR respectively), 200µM of KAPA 10mM dNTP mix, and 0.5 units of KAPA 
Long Range HotStart (both from KAPA Biosystems, Wilmington, Massachusetts), added 
in the order given. Unless otherwise stated, thermal cycling conditions consisted of a 
denaturation step of 94°C for 2 minutes, then 35 cycles of 94°C for 30 seconds, a 59°C 
annealing temperature for 30 seconds, and an extension step at 68°C for 7 minutes, with 
a final extension of 72°C for 7 minutes. 
2.5.4 Other PCR methods used for full length BRCA1 mRNA 
Reaction components were identical to either Section 2.5.2 or Section 2.5.3, and are 
specified for each experiment in the results sections. Touchdown PCR cycling conditions 
differed from the standard or alternative PCR cycling conditions by starting with 8 
cycles in which the annealing temperature decreased by 1°C each cycle, then 30 cycles 
using the lowest annealing temperature reached. The starting temperatures ranged 
from 66°C to 62°C. Temperature gradient PCR cycling conditions differed by changing 
the annealing temperature across a plate so each sample has a different temperature at 
the annealing step, which ranged from 55°C to 63°C, and 35 cycles were used. 
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2.6 Agarose Gel Electrophoresis 
 A 1% agarose gel was used for resolving PCR products >1kb, while a 2% agarose gel 
was used for resolving products <1kb. 2µl of SYBR®Safe DNA Gel stain (Invitrogen, 
ThermoFisher Scientific, Auckland) was added to heat-dissolved agarose powder 
(Duchefa Biochemie Agarose SPI, Total Lab Systems Ltd, Haanlen, NL) in 1x TAE buffer. 
This solution was then allowed to set in an EASY-CAST™ Electrophoresis System (Owl 
Separation Systems, Portsmouth, NH, USA). The gel was then submerged in 1x TAE 
buffer.  
1µl of 6x KAPA loading dye (KAPA Biosystems, Wilmington, Massachusetts) was added 
to 2µl of PCR product and 3µl of MPW, and loaded into wells. 2µl of KAPA Universal DNA 
ladder (KAPA Biosystems, Wilmington, Massachusetts) was loaded into at least one well 
in each gel and run alongside the products. This system was electrophoresed (using the 
PowerPac Basic, BioRad, NSW, Australia) at 80V for 30-60 minutes until the dye had 
visibly migrated at least two thirds the length of the gel. For higher separation of bands 
of similar size, the leading edge of the dye was occasionally run off the end of the gel.  
Visualisation of the DNA bands was achieved using the gel documentation system 
Alliance 4.7, UVItec (Cambridge).  
2.7 Extraction of DNA from agarose gel 
Obtaining DNA from agarose gels was sometimes required for accurate Sanger 
sequencing. There were two techniques used for this purpose, detailed below. Both DNA 
extraction procedures were performed using a white/UV Transilluminator box (Alpha 
Innotech, San Leandro, CA). 
2.7.1 Band stab 
Sterile 6 gauge syringe needles were inserted into DNA bands of interest, swirled in 50ul 
of MPW and the needles discarded. 1µl of the resulting sample was then used in a repeat 
PCR with the same protocol used to produce the original band.  
2.7.2 Full band extraction 
In some cases, bands of interest were re-amplified using band stab PCR as described 
above. When such bands were still not pure enough for sequencing, they were excised 
from the gel using a sterile scalpel in order to isolate the single band of interest. This 
was purified from the agarose gel using the MEGAquick-spin Total fragment DNA 
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Purification kit, (iNtRON Biotechnology Inc., Korea). When required, recovered DNA 
was concentrated using an Eppendorf Concentrator 5301 (Hamburg, Germany). 
2.8 Sanger Sequencing 
Sanger sequencing using the Applied Biosystems Big Dye Terminator version 3.1 (BDT) 
was used to confirm PCR products were from BRCA1 and BARD1 mRNA prior to MinION 
nanopore sequencing. PCR products were diluted 1:3 in MPW and 1µl of this was added 
to a 10µl reaction volume containing 0.5µM primer, 2µl of BDT 5x sequencing buffer, 
and 0.5µl of BDT terminators. These reactions were cleaned using the illustra Sephadex 
G50 spin column (GE Healthcare, Sigma-Aldrich, Auckland) and eluted in 30µl of MPW. 
This final volume was electrophoresed using a 50cm array on the Hitachi 3130XL 
Genetic Analyzer (Applied BioSystems). Preparation was carried out according to the 
manufacturer’s instructions. 
The program Geneious® version 9.1.5 was used (Biomatters, Ltd) [144], to analyse the 
raw sequence data, in conjunction with the BLAT tool [145] on UCSC genome browser 
[146] (https://genome.ucsc.edu/cgi-bin/hgBlat?command=start) to identify the gene 
each sequence matched. In the case of confirming isoforms, the Geneious®: Multiple 
Sequence Aligner tool was used to match the Sanger sequence of the sample with the 
predicted isoform as a reference sequence. 
2.9 MinION sequencing (R9 model) 
PCR samples to be sequenced required a clean-up step before beginning the MinION 
library preparation. The clean-up protocol was based on the bead clean-up step in the 
End-prep section of the Amplicon protocol, and can be found separately in Appendix B. 
Once the initial clean-up was done the samples were quantified using the Qubit® 
Fluorometer HS Assay Kit (Life Technologies, ThermoFisher Scientific, Auckland) then 
used in the full Amplicon protocol (R9 version) which can be found in Appendix C. The 
Nanopore Sequencing Kit SQK-NSK007 (R9 Version) was used in library preparation. 
The flow cell was of the code FLO-MIN104. The MinKNOW program used for running 
the MinION was NC_48Hr_Sequencing_Run_FLO_MIN104.py. The flow cell was topped 
up when the number of pores being used was less than 20, until the entire sample was 
used. The raw electrical signal was uploaded to Metrichor (version 1.107), a proprietary 
program run on servers at ONT, using the 2D Basecalling RNN for SQK-NSK007 which 
basecalled and returned the file in .fast5 file format.  
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2.10 MinION Sequence Analysis 
Figure 2.2 describes the steps derived in Chapter 3 to analyse the basecalled data files. 
The software package Poretools [137] was used to convert .fast5 into .fasta files. All 
computer commands used and Excel methods can be found in Appendix D. The multi-
fasta reference file (Appendix D.1) contains BRCA1 exon 11 split into three segments, 
labelled Exon11a, Exon11b, and Exon11c. These segments corresponded to published 
data on the common splice sites of the isoform Δ11q [60], where the 3’ end of exon 11 
is spliced out, and the isoform 11Δ3110, where an intronisation occurs in the middle of 
exon 11 (see Table 1.1 for an explanation of intronisations). 
 
Figure 2.2: Flow chart describing MinION data analysis final pipeline.  
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2.10.1 Local BLAT parameters 
The standalone BLAT program (version 36) was downloaded from 
http://hgdownload.cse.ucsc.edu/admin/exe/ [145] and used on a local Linux computer 
rather than on the UCSC Genome Browser website. Details about computer commands 
used can be found in Appendix D.2. The tabular format produced by BLAT is modelled 
on the BLAST tabular output. The graphical format is a .psl file, which was converted to 
a .sam file using the psl2sam.pl program (obtained June 2016). This creates .sam file of 
a format which uses M to denote both matches and mismatches in the CIGAR string. 
Samtools (version 0.1.18) was used to adjust .sam files in order to be read by visual 
programs. 
2.10.2 Tabular format data analysis using R-Studio and Excel 
The tabular output from BLAT was imported into R-Studio. The first two columns of 
read name and reference were used to generate a list of the references (in this case, each 
exon and intron) which matched to each read in the statistical program R (version 3.2.2) 
using R-Studio. This table was then opened in Microsoft Office Excel 2013, which was 
used to group the reads by references matched and then to summarise the results into 
standard isoform notation. The R script and exact methods of Excel analysis can be 
found in Appendix D.5 and D.6.  
2.10.3 Graphical format data analysis using Samcat.py 
Samcat.py (Appendix D.7) is a program developed in collaboration with a Software 
Engineer during the course of this project to concatenate all the .sam files associated 
with a single read, when mapped to different reference sequences, by joining the CIGAR 
strings together. The result is a .sam file which contains just one line of information per 
read. Due to the nature of this process, Samcat.py also eliminates spurious alignments, 
and therefore acts as a filtering step as well. The .sam files were viewed in Integrated 
Genomics Viewer (IGV) version 2.3.82. More information on the development of 
Samcat.py can be found in Chapter 4. 
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 Chapter 3: Results 
3.1 Introduction 
There were two main parts to this project. The first involved the RT-PCR amplification of the 
5.8kb long BRCA1 amplicon (includes all of the coding region) and the 2.0kb long BARD1 
amplicon. If these could be produced it was assumed that other, alternatively spliced isoforms 
would be produced as well. 
MinION data analysis of cDNA was the second part of this project. This posed a major 
challenge because the technology is so new that methods of analysis for full length mRNA 
data, (not data on individual splice junctions), is at a very early stage and established methods 
of analysis are not available. As a consequence, my project required development of methods 
to properly analyse this type of MinION data. 
3.2 PCR and identification of BRCA1 and BARD1 from cDNA 
Oligo(dT) primers, random hexamers and gene specific primers were used to synthesise 
cDNA in three separate reaction tubes. For each reaction there was also a control reaction 
with no reverse transcriptase enzyme added to ensure that products were the result of cDNA 
synthesis and not of any genomic products that may be present. Relatively short PCR 
reactions (under 500kb) were then used to check that the synthesis of cDNA was successful. 
These reactions used primers designed to amplify the 3’ end and the 5’ end of the BRCA1 
transcript separately. Primers designed for the BARD1 full transcript were also used to test 
cDNA synthesis from oligo(dT) primers. 
3.2.1 BRCA1 3’ end and 5’ end PCR products 
Products were detected from all cDNA samples. PCR of the 3’ end of BRCA1 resulted in the 
same two visible bands on the agarose gel for each sample, at about 500bp and 400bp 
respectively (Figure 3.1A). The lane containing cDNA made with oligo(dT) primers showed 
an intense, smeared band, while gene specific priming was less intense, and that from random 
hexamer priming was comparatively faint. Figure 3.2A shows the PCR of the 5’ end of BRCA1 
that resulted in six visible bands from oligo(dT) priming, one bright and two faint bands from 
gene specific priming, and two barely visible bands from the random hexamer primed sample, 
all migrating between a 200bp and 600bp fragment size. There was significantly more 
product produced in oligo(dT) primed samples than there was in the random hexamer and 
gene specific primed samples for both the 3’ end and 5’ end. These results indicated that the 




3.2.1.1 Sanger sequencing 
In order to confirm these products were produced from BRCA1 transcript a number of bands 
from each of the 3’ and 5’ PCR reactions were extracted for Sanger sequencing. Initially this 
was carried out using the band stab technique. Both bands produced in 3’ end PCR by gene 
specific priming in Figure 3.1A were extracted using the band stab method and underwent a 
second PCR to generate sufficient material for sequencing. Figure 3.1B shows the PCR result 
of the product indicated on Figure 3.1A, which was pure enough to be successfully Sanger 
sequenced (Figure 3.1C); however, the other band was not successfully sequenced (data not 
shown). A BLAT alignment verified that the sequence obtained from the pure band in Figure 
3.1B matched to the BRCA1 gene (Figure 3.1D). Of the 6 bands produced in 5’ PCR (Figure 3.2) 
by Oligo(dT) priming, only one band successfully produced usable sequence (indicated on 
Figure 3.2A). This was extracted using the band stab method, and the second PCR (Figure 
3.2B) produced 5 bands in total. The band of interest was then fully extracted and purified 
before Sanger sequencing (Figure 3.2C). The resulting sequence was confirmed to belong to 
the BRCA1 gene using a BLAT alignment (Figure 3.2D). These two results enabled us to move 




Figure 3.1: BRCA1 3' end Amplification and Sequencing.  
A: PCR check of 3’ end BRCA1 cDNA synthesis. 5µl of cDNA was used. DNA extracted by band stab is indicated on the 
figure. RT+ refers to reactions containing reverse transcriptase, RT- refers to negative control reactions without reverse 
transcriptase. B: PCR result of the band stab in A. For both A and B the standard PCR protocol for product size <3kb was 
used, with an annealing temperature of 65°C and extension time of 30 seconds. Primers were BRCA1_20F and 
BRCA1_24pR. 5µl of each PCR reaction was run on 1% agarose gels. Size in base pairs (bp) of relevant bands in the 
marker lane (Ladder) is indicated. C: Sanger sequencing result of this band primed with BRCA1_20F visualised in 
Geneious™. D: BLAT alignment tool showing the sequence match using the UCSC Genome Browser. Enlarged pictures 





Figure 3.2: BRCA1 5' end Amplification and Sequencing.  
A: PCR check of 5’ end BRCA1 cDNA synthesis. 5µl of cDNA was used. DNA extracted by band stab is indicated on the 
figure. 5µl of each PCR reaction was run on a 1% agarose gel. RT+ refers to reactions containing reverse transcriptase, 
RT- refers to negative control reactions without reverse transcriptase. B: PCR result of the band stab in A. 5µl of each 
PCR reaction was run on a 2% agarose gel. The band indicated was cut out and purified before sequencing. For both A 
and B the standard PCR protocol for product size <3kb was used, with an annealing temperature of 64°C and extension 
time of 32 seconds. Primers were BRCA1_1F and BRCA1_5R. Size in bp of relevant bands in the marker lane (Ladder) is 
indicated. C: Sanger sequencing result of this band primed with BRCA1_5R visualised in Geneious™. D: BLAT alignment 
tool showing the sequence match using the UCSC Genome Browser. Enlarged pictures are shown of individual exon 




3.2.2 BARD1 PCR products  
On the basis of previous results, oligo(dT) primed cDNA was also used to generate BARD1 PCR 
products. Primers were designed so the length of the amplicon was reduced to 2.0kb from the 
full length 2.6kb transcript (see Figure 2.1B). Multiple bands were generated by BARD1 PCR, 
indicative of multiple isoforms (Figure 3.3A). One of these bands was ~2000bp, and seemed 
likely to represent the full length transcript. This experiment was replicated a number of 
times throughout the course of this project in order to gain enough product for MinION 
sequencing, and each replicate produced consistent results (data not shown). 
3.2.2.1 Sanger sequencing 
In order to confirm these products were produced from BARD1 transcript a number of bands 
from the initial PCR reaction were extracted from the gel for Sanger sequencing. Initially this 
was carried out using the band stab technique. Unfortunately all resulting samples had 
contamination from other bands, and could not be directly used in Sanger sequencing. These 
bands sometimes required two consecutive band stabs and a full band extraction before 
sequencing. The last corresponding PCR reaction was also sequenced in an attempt to ensure 
success. 
All bands in Figure 3.3 eventually produced at least two sequences that were of good quality, 
as demonstrated by Figure 3.3C. BLAT analysis indicated that all bands matched BARD1 
demonstrated in Figure 3.3D. Some exon skipping was also detected, confirming that the 
multiple bands visible represented different isoforms (data not shown). This result confirmed 








Figure 3.3: BARD1 Amplification and Sequencing.  
A: PCR check of BARD1 cDNA synthesis. 5µl of cDNA was used. DNA extracted by band stab is indicated on the figure. 
RT+ refers to reactions containing reverse transcriptase, RT- refers to negative control reactions without reverse 
transcriptase. B: PCR result of the band stab in A. The band indicated was cut out and purified before sequencing. For 
both A and B the standard PCR protocol for product size <3kb was used, with an annealing temperature of 66°C and 
extension time of 2 minutes. Primers were BARD1_1F and BARD1_11R. 5µl of each PCR reaction was run on 1% agarose 
gels. Size in bp of relevant bands in the marker lane (Ladder) is indicated. C: Sanger sequencing result of this band 
primed with BARD1_11R visualised in Geneious™. D: BLAT alignment tool showing the sequence match using the UCSC 
Genome Browser. Enlarged pictures are shown of individual exon alignments. The black bar at the top of each picture 




3.2.3 Titration to determine optimal amount of cDNA 
To optimise the RT-PCR a titration 
experiment was performed with varying 
amounts of cDNA. For simplicity, this 
was performed using BARD1 primers 
and reaction conditions. This 
experiment (Figure 3.4) demonstrated 
that 3µl of cDNA per reaction was 
sufficient to gain satisfactory results.  
3.2.4 Full length BRCA1 PCR 
The BRCA1 reverse primer is situated 
near the 5’ end of exon 24 (Figure 2.1), 
reducing the size of the 7.2kb full length 
transcript to an amplicon size of 5.8kb. A 
different pattern of bands was observed 
each time a new BRCA1 PCR reaction 
was performed (Figure 3.6).  As a result, 
a number of variations to the standard PCR for full length BRCA1 mRNA were used to generate 
the final pool of PCR products used in MinION sequencing. Initially, the aim was to ensure that 
a band the size of the full length PCR product was present. However, when the results began 
to show a wide range of variation between samples, a general goal of generating the full length 
product as well as a wide selection of potential isoforms was established. Stochastic 
amplification of various BRCA1 isoforms in the initial PCR cycle was decided to be the likely 
cause of the wide variation. 
 A summary of the number and approximate size of the bands present across all full length 
BRCA1 PCR reactions can be found in Table 3.1. The PCR protocols to generate these bands 
were based on either the standard PCR for full length BRCA1 mRNA, or the alternative PCR for 
full length BRCA1 mRNA. Along with the normal standard and alternative protocol, 
temperature gradients and touchdowns for each protocol were used. Some of these results 
are demonstrated in Figure 3.6; the remaining experiments can be found in Appendix E. 
Figure 3.4: Titration of cDNA amount.  
Standard PCR for products <3kb was performed using 
the primers BARD1_1F and BARD1_11R. Annealing 
temperature was 66°C and extension time was 2 
minutes. 2µl of each reaction was run on a 1% agarose 
gel. Size in bp of relevant bands in the marker lane 




Table 3.1: Number of bands per estimated size across all BRCA1 long range PCRs. 
 
3.2.4.1 Sanger sequencing 
No attempt was made to purify long PCR products as done for the short amplicons. As each 
reaction was generated using the same forward and reverse primer there was enough 
similarity at the beginning and end of amplicons to generate sufficient sequence data to 
confirm the presence of BRCA1. A total of 16 samples representative of the range of PCR 
protocols used were chosen for Sanger sequencing, and 11 of these were of sufficient quality 
to match to BRCA1 using the BLAT alignment (data not shown).  
3.3 MinION  
3.3.1 Samples sequenced 
Two MinION samples were run during this project. The first 
comprised both BRCA1 and BARD1 PCR reactions, as indicated 
in Figure 3.6. The first selection of BRCA1 reactions was 
pooled together, all BARD1 reactions were pooled together, 
and the initial clean-up step was performed on each of these 
two pooled samples. Samples were checked by gel 
electrophoresis prior to the MinION run (Figure 3.5). A 
notable feature of this result is the high molecular weight 
smear present in the BARD1 sample, which did not, however, 
seem to affect sequencing or downstream analyses. The final 
concentration of DNA in the cleaned BRCA1 samples was 
37.8ng/µl, with a total of 18µl of sample. The final 
concentration of DNA in the BARD1 sample was 116ng/µl, 
with a total of 26µl of sample. There was not enough BRCA1 to 
run on the MinION on its own, so the decision was made to 
pool it with BARD1, regardless of the smear present in the 
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length cDNA reference sequences were aligned to each other using the proposed method of 
alignment at the time (LAST aligner [147]), to determine if they could be distinguished if they 
were pooled. They have similar protein domains and may have shown a relationship at the 
nucleotide level, which would have the potential to confuse the analysis if the two samples 
were pooled. However, no alignments were found (data not shown).  
All 18µl of the BRCA1 sample and 5.8µl of BARD1 sample was used to get an equal amount of 
DNA from each, then it was made up to 50µl with MPW to begin the MinION Amplicon 
protocol. The second sample run on the MinION contained BRCA1 reactions only, as indicated 
in Figure 3.6 and related figures in Appendix E. These reactions were pooled and cleaned as 
described above, and the concentration of DNA in the cleaned sample was 54.8ng/µl in a total 
sample size of 30µl. This was made up to 50µl with MPW to begin the MinION Amplicon 
protocol. The MinION flow cell was washed according to the manufacturer’s instructions 








Figure 3.6: Varying long range BRCA1 PCR results.  
Samples that underwent Sanger sequencing and MinION sequencing are indicated. MinION sequenced samples are 
further identified by which pooled sample they contributed to. Size in bp of relevant bands in the marker lane (Ladder) 
is indicated on each figure. 2µl of each reaction was run on 1% agarose gels. A: Temperature gradient based on the 
standard PCR for full length BRCA1. Annealing temperature is displayed for each sample. B and C: Temperature 
gradient based on the alternative PCR for full length BRCA1, carried out on two different days. Annealing temperature 
is displayed for each sample. D: Standard PCR for full length BRCA1. 
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3.3.2 Statistics from the 2 runs 
The first MinION run produced a total of 105,482 reads, of which 23,978 passed the quality 
control filters for 2D reads by Metrichor analysis and 81,504 failed. Of the total, 4,302 aligned 
to BRCA1 in BLAT analysis, and 54,505 aligned to BARD1, leaving 46,675 unaligned. The 
second MinION run produced a total of 12,022 reads, of which 995 passed the quality control 
filters for 2D reads by Metrichor analysis and 11,027 failed. Of the total, 2115 aligned to 
BRCA1 in BLAT analysis, and 837 aligned to BARD1, leaving 9070 unaligned. Though the 
second sample contained BRCA1 PCR products only, some of the BARD1 amplicons from the 
previous run were not able to be fully washed out, accounting for the number of reads in the 
second run which aligned to BARD1. 
3.3.3 MinION read data analysis 
The flow chart in Figure 3.8 describes the trial-and-error approach to developing the final 
data analysis pipeline described in Chapter 2. Many alignment programs and reference 
sequence arrangements were tried before BLAT alignment was selected. Table 3.2 and Table 
3.3 summarise these programs, the parameters used and the reason each program was 
discarded before the final data analysis. Many of these programs produced a similar final 
result of aligning to just one exon, demonstrated by Figure 3.7, generated using the LAST 
analysis [147]. For the final analysis using a local BLAT download, the two MinION read data 




Figure 3.7: LAST alignment example result.  
Reference is indicated on the figure, located at BRCA1 Exon 11. Each individual read was assigned a number, and some 
of the reads that align to BRCA1 exon 11 are shown. This figure was generated using the program LAST to align the 




Figure 3.8: Iterative development of final data analysis pipeline.  
Arrows from the centre indicate a new trial, while arrows between alignments represent trials that influence decisions of the next trial. Each box has a number corresponding to a row in Table 
3.2 or Table 3.3. Grey represents trials leading to "dead ends". Blue indicates trials that lead to a successful analysis.
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Program – reference used Parameters used Description of result 
1 LAST (version last-621) [147] 
– cDNA reference 
– whole gene reference 
lastdb -Q 0 
lastal -s2 -T0 -Q0 -a1 
last-map-probs 
(default) 
Can identify some full length 
reads, but not able to see 
variations well. Only shows best 
part of alignment (Figure 3.7). 
No way to group similar reads. 
2  LAST (version last-621) [147] – 
whole gene reference 
As in number 1, with 
an e-value of 120. 
No significant difference to 
number 1. 





nanopore reads.  
No significant difference to 
number 1. 
4  Bwa-sw (version 0.7.7) [149] – 
whole gene reference 
defaults No significant difference to 
number 1. 
5  Bwa-mem (version 0.7.7) [149] – 
whole gene reference 
-x ont2d No significant difference to 
number 1, did not split 
sequences and instead deleted 
adjacent sequence 
6 STAR alignment (v. 2.2) [150] – 
whole gene reference 
Indexed reference 
only 
Program crashed while 
indexing reference. 
7 Salmon (v. 0.6.0) [151] – multi-
fasta reference with exons only 
quant -p 4 -k 5 --
sensitive -l U 
Quantitative, gave a number of 
reads which aligned to each 
exon. Not helpful. 
8 Kallisto (v. 0.42.4) [152] -  multi-
fasta reference with exons only 
Note: used .fastq files instead of 
.fasta 
quant  -l 5000 -s 
2000 --plaintext --
single --pseudobam 
Did not split sequences and 
instead deleted adjacent 
sequence 
9 LAST (version last-621) [147] 
 – whole gene reference 
Note: used .fastq files instead of 
.fasta 
As in number 1, 
using function “last-
split -c0,” after last-
map-probs. 
No significant difference to 
number 1. 
10 HISAT (v. 2.0.3) (through Galaxy 






Output file had no information. 
11 Geneious: Map-to-genome function 
(v. 9.1.0) [144] – whole gene 
reference 





Table 3.3: Iterative development of analysis pipeline (successful) 
Flow chart 
code 
Program – reference used Parameters used Description of result 
12 BLAT alignment (v. 36) [145] – 
hg19 human genome 
Defaults Aligned reads against correct 
regions of genome, showed 
connection between exons. 
13 BLAST alignment (v. 2.2.28) 
[155] – multi-fasta file with 
exons only 
Defaults Default output: shows each 
individual alignment.  
Tabular output: gives 
information able to be 
manipulated to give a 
summary. Stringent 
parameters missed 
alignments to exons found in 
BLAT. 
14 BLAT alignment (v. 36) [145]  
- whole gene reference 
Defaults. 
Output to four file 
types: pslx, MAF, 
standard BLAST, 
and BLAST tabular. 
MAF format: similar to no. 1.  
Standard BLAST: not helpful. 
Pslx showed alignments not 
consistent to exons. 
BLAST tabular: not helpful as 
reference was all the same, 
difficult to determine specific 
places of alignment. 
15 BLAT alignment (v. 36) [145] 
with UCSC website parameters – 






Output for one read was 
identical to output generated 
by the same read when using 
the tool on the Genome 
Browser website. 
16 BLAT alignment (v. 36) [145]  
– multi-fasta reference with 
exons and introns (Appendix 
D.1) 
Defaults Pslx visual output: multi-fasta 
file gave individual 
alignments per reference. 
BLAST tabular output: as in 
no. 13. 
17 BLAT alignment (v. 36) [145] – 
multi-fasta reference (Appendix 
D.1) 
Use UCSC website parameters. 





 Pslx visual output: multi-
fasta file gave individual 
alignments per reference. 
Cannot see multiple 
alignments per read. 
BLAST tabular output: as in 
number 13. 
18 Tabular output manipulated in R 
(v. 3.2.2) and Excel (2013) 
See Appendix D.5 
and D.6 for R script 
and Excel analysis. 
Summary of isoforms ordered 
by number of reads 
associated with each isoform. 
19 Pslx converted to .sam file using 
Perl program psl2sam.pl 
(obtained June 2016) [156]. 
Program Samcat.py developed to 
join individual alignments 
together 
See Appendix D.7 
for Samcat.py 
program. 
Able to now look at full 
isoform alignments. Also 
filtered out bad alignments. 
Final method 
implemented 
BLAT alignment (v. 36) to multi-
fasta reference (Appendix D.1) 
 
UCSC website 
parameters and two 
output formats 
 
Using both outputs enabled a 
comprehensive analysis of the 




3.3.4 BLAT Tabular output 
Table 3.4 and Table 3.5 summarise the results from BRCA1 and BARD1 analyses 
respectively. A total of 34 BRCA1 isoforms were detected with a read depth greater than 
five reads per isoform. A total of 39 BARD1 isoforms were detected with a read depth 
greater than 23 reads per isoform. A greater number of reads was chosen for the read 
depth threshold because of the significantly greater amount of BARD1 in the sample. 
There were 24 BRCA1 isoforms and 18 BARD1 isoforms that have not been previously 












Δ11q 86 Colombo, et. al., [60] 
Δ9,10,11q 79 Colombo, et. al. [60] 
full length 52 Miki, Y., et. al., (1994), [2] 
11Δ3110 34 Colombo, et. al. [60] 
Δ10-17 29 Not found 
Δ9,11q 28 Colombo, et. al. [60] 
Δ9,10,11q,12-15 19 Not found 
Δ9,10,11q,19 18 Not found 
Δ11q,19 17 Not found 
Δ9,10,11q, 21 16 Not found 
Δ9-11 16 Colombo, et. al. [60] 
Δ11q,21 14 Not found 
Δ3,11Δ3110 13 Not found 
Δ3 12 Colombo, et. al. [60] 
Δ19 12 Colombo, et. al. [60] 
Δ11q, 21 12 Not found 
Δ9,10 10 Colombo, et. al. [60] 
Δ9,10,11q,19,21 10 Not found 
Δ2,9,10,11Δ3110/3240,Δ14,20,22 10 Not found 
Δ11q,14,21 10 Not found 
Δ9,10,21 9 Not found 
Δ3,9,10,11q 9 Not found 
Δ2,9,10,11q, 21 9 Not found 
Δ21 9 Colombo, et. al. [60] 
Δ11 9 Colombo, et. al. [60] 
11Δ3110/3240, Δ15-17 8 Not found 
Δ2-19 8 Not found 
Δ9,10,11q,21 7 Not found 
11Δ3110/3240,19 7 Not found 
Δ2-6 7 Not found 
Δ11q,23 7 Not found 
Δ10-17,21 7 Not found 
Δ9,11q, 21 6 Not found 
Δ10-17,19 6 Not found 
Δ11q,17 6 Not found 
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Table 3.5: BARD1 isoforms found in BLAT tabular output * 
*Table continued on following page  
Name 
No. reads per 
isoform 
Previously described? 
Full length 4835 Wu, L.C., (1996), [5] 
 
Δ4 2004 Lombardi, G., et. al., (2007) [97] 
Li, L., et. al., (2007) [98] 
Lattimore, V., (2016) [102] 
Δ3,4 1010 Lombardi, G., et. al., (2007) [97] 
Bosse, K. R., et. al., (2012) [95]  
Identified as pathogenic. 
Δ4-9 589 Sporn, J.C., et.al., (2011) [96]  
Zhang, Y., et.al., (2012) [94] 
Bosse, K. R., et. al., (2012) [95] 
Pilyugin, M., et. al., (2014) [92] 
Δ2 586 Li, L., et. al., (2007) [98] 
Pilyugin, M., et. al., (2014) [92] 
Identified as pathogenic. 
Δ3 514 Sporn, J.C., et.al., (2011) [96] 
Zhang, Y., et.al., (2012) [94] 
Bosse, K. R., et. al., (2012) [95] 
Lattimore, V., (2016) [102] 
Δ2-4 471 Lombardi, G., et. al., (2007) [97] 
Sporn, J.C., et.al., (2011) [96] 
Bosse, K. R., et. al., (2012) [95] 
Δ2-9 335 Lombardi, G., et. al., (2007) [97] 
Sporn, J.C., et.al., (2011) [96] 
Zhang, Y., et.al., (2012) [94] 
Bosse, K. R., et. al., (2012) [95] 
Δ3-9 289 Sporn, J.C., et.al., (2011) [96] 
Bosse, K. R., et. al., (2012) [95] 
Δ2,4 286 Not found 
 
Δ3-6 271 Lombardi, G., et. al., (2007) [97] 
Sporn, J.C., et.al., (2011) [96] 
Bosse, K. R., et. al., (2012) [95] 
Δ2-6 263 Lombardi, G., et. al., (2007) [97] 
Sporn, J.C., et.al., (2011) [96] 
Zhang, Y., et.al., (2012) [94] 
Bosse, K. R., et. al., (2012) [95] 
Δ3-7 205 Bosse, K. R., et. al., (2012) [95] 
Identified as pathogenic. 
Δ4-6 176 Bosse, K. R., et. al., (2012) [95] 
Identified as pathogenic. 
Δ2,3 163 Sporn, J.C., et.al., (2011) [96] 
Zhang, Y., et.al., (2012) [94] 
Bosse, K. R., et. al., (2012) [95] 
10 99 Lattimore, V., (2016) [102] 
 
Δ5 98 Ratajska, M., et. al., (2015) [91] 
Identified as pathogenic. 






No. reads per 
isoform 
Previously described? 
Δ10 91 Not found 
 
Δ2,4-9 81 Not found 
 
4 72 Not found 
 
Δ2-10 71 Not found 
 
Δ9 60 Not found 
 
Δ2-7 51 Feki, A., (2005) [16] 
Identified as pathogenic. 
Δ410 45 Not found 
 
Δ2,5 45 Not found 
 
Δ4,7 44 Not found 
 
Δ8 43 Sporn, J.C., et.al., (2011) [96] 
Ratajska, M., et. al., (2015) [91] 
Δ4,9 41 Not found 
 
Δ4,10 39 Not found 
 
Δ2,10 38 Not found 
 
Δ4,5 32 Not found 
 
Δ2,4-6 32 Not found 
 
Δ3-4,10 30 Not found 
 
Δ2-5 28 Bosse, K. R., et. al., (2012) [95] 
 
Δ2-4,8 27 Sporn, J.C., et.al., (2011) [96] 
 
Δ5-9 26 Not found 
 
2 26 Bosse, K. R., et. al., (2012) [95]  
Insertion not found independently before, has 
been found in association with Δ4q,6q. 
Δ3-5 26 Bosse, K. R., et. al., (2012) [95] 
 




3.3.5 BLAT Graphical output and Samcat.py 
The program Samcat.py that was developed during the course of this project was 
required to obtain a complete view of the transcript reads spanning the entire gene. 
Without the program, the reads could only be viewed according to each reference 
sequence, due to the necessary structure of the multi-fasta file (data not shown). 
Samcat.py was applied to the entire BLAT graphical output dataset, but at this stage, 
enough data was obtained for the focus to be turned solely on six BRCA1 isoforms, so 
only these particular groups, identified from the BRCA1 tabular results, were analysed. 
The reads associated with each group were transferred into .sam files of isoform groups 
to be viewed in IGV separately. The six novel BRCA1 isoforms that were chosen to be 
further analysed were: Δ11q,21 (Figure 3.9), Δ10-17 (Figure 3.10), Δ3,11Δ3110 
(Figure 3.11), Δ11q,14,21 (Figure 3.12) Δ3,9,10,11q (Figure 3.13), and Δ11q,19. This 
format allowed identification of a number of possible splice acceptor and donor shifts. 
Some of these shifts occurred in all reads in an isoform group, while others only 
occurred in some. These changes are described in Table 3.6. It will require further 
analysis to determine if the patterns of multiple splice shifts occur are consistent 
between molecules, though a cursory inspection suggests that the patterns are not 
consistent. Discrepancy between the splice shifts seen in the figures and those described 
in Table 3.6 is a result of the alignment program aligning bases in adjacent exons twice, 
and will be discussed further in Chapter 4. Figure 3.9A is an example of the entire gene 
view for isoform Δ11q,21 in IGV, with large portions of introns removed for viewing 
purposes, and is not shown for other isoforms. Of the full length group, 22 reads were 
selected for further examination (Figure 3.14). Upon close examination of exons in the 
full length group variations were apparent in exons 1, 6, 8, 10, and 16. No single read 
displays a full alignment to every exon due to a consistent absence of three bases in the 
3’ end of exon 10 (Figure 3.14D). Other exon alignments showed little variation in splice 
shifts between reads (data not shown). It is important to note that due to the format of 
the .sam files used, mismatched base information is not available, and is shown in Figure 





Figure 3.9: Isoform Δ11q,21 BLAT final graphical result.  
The position of each exon is shown as a blue bar and is indicated on the figure. A: Full gene analysis picture from 
IGV, with large intron stretches removed. Exon 11 and the intron 21 insertion positions are indicated. B: Detail 
view of exon 1 specific reads, deletion of 6 bases indicated by a black box. C: Detail of exon 2 specific reads, 
deletion of 12 bases indicated by a black box. D: Detail of exon 16 specific reads, deletion of 2 bases indicated by 
a black box. E: Detail of specific reads retaining intron 21. The black box indicates 5 bases at the 5’ end of the 




Figure 3.10: Isoform Δ10-17 BLAT final graphical result.  
The position of each exon is shown as a blue bar and is indicated on the figure. A: Detail view of exon 1 specific 
reads, occasional deletion of 6 bases indicated by a black box. B: Detail of exon 3 specific reads, occasional 
deletion of 4 bases indicated by a black box. C: Detail of exon 6 specific reads, occasional deletion of 4 bases 




Figure 3.11: Isoform Δ3,11Δ3110 BLAT final graphical result.  
The position of exon 5 is shown as a blue bar and is indicated on the figure. Detail view of exon 5 specific reads, 




Figure 3.12: Isoform Δ11q,14,21 BLAT final graphical result.  
The position of exon 1 is shown as a blue bar and is indicated on the figure. Detail view of exon 1 specific reads, 




Figure 3.13: Isoform Δ3,9,10,11q BLAT final graphical result.  
The position of the exon is shown as a blue bar and is indicated on the figure. A: Detail view of exon 1 specific 
reads, deletion of 6 bases indicated by a black box. B: Detail view of exon 14 specific reads, possible occasional 






Figure 3.14: Exon variations in 22 reads from the full length group graphical result.  
The position of the exon is shown as a blue bar and is indicated on the figure. A: Detail view of exon 1 specific 
reads, occasional deletion of 6 bases indicated by a black box. B: Detail of exon 6 specific reads, occasional 
deletion of 4 bases indicated by a black box. C: Detail view of exon 8 specific reads, occasional deletion of 3 bases 
indicated by a black box. D: Detail of exon 10 specific reads, consistent deletion of 3 bases indicated by a black 
box. E: Detail of exon 16 specific reads, occasional deletion of 2 bases indicated by the black box. 
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Table 3.6: BRCA1 isoform splice acceptor/donor shifts identification 
                                                          
a Number of reads identified by the tabular output. The graphical output revealed reads that were not of the isoform indicated. 
b For the purposes of this identification, 11q has been treated as a normal exon splice rather than a donor shift. 
c Not previously described in the literature. 
d There appears to be one read aligning to the entire exon in Figure 3.9, however this particular read does not belong in this isoform group as it does not contain the intron 21 
insertion. 
e Figure 3.9D shows only 2 bases deleted at this position, though the last base in this triplet (G) is also present at the end of exon 15, and so will have aligned twice due to the nature of 
the reference file. This phenomenon is discussed further in Chapter 4: Discussion. 
f Appears to be a 7bp shift but could be a 9bp shift due to the presence of a polyA tract in adjacent exon 13. Δ14p was described previously as a 3bp deletion 60. Colombo M, Blok MJ, 
Whiley P, Santamariña M, Gutiérrez-Enríquez S, Romero A, et al. Comprehensive annotation of splice junctions supports pervasive alternative splicing at the BRCA1 locus: a report 
from the ENIGMA consortium. Human Molecular Genetics. 2014;23(14):3666-80., so this variation has been distinguished here as Δ14Ap. These changes are further discussed in 
Chapter 4: Discussion. 
 
 
Previous name No. of readsa Acceptor/Donor 
shiftsb 
Acceptor/Donor shift description New name Figure 
reference 
Δ10-17 29 Δ1Aq 
Δ3pc 
Δ6qc 
Δ1Aq: 6bp shift, occurs in some transcripts 
Δ3p: 4bp shift, occurs in some transcripts 
Δ6q: 4bp shift, occurs in some transcripts 
- Figure 3.10 
Δ11q,19 17 None detected - - - 
Δ3,11Δ3110 13 Δ5q Δ5q: 21bp shift, occurs in most transcripts - Figure 3.11 
Δ11q,21 12 Δ1Aq 
Δ2p 
Δ16pc 
Δ1Aq: 6bp shift, occurs in all transcripts 
Δ2p: 13bp shift, occurs in all transcriptsd 
Δ16p: 3bp shifte, occurs in all transcripts but one 
Δ1Aq,2p,11q,21 Figure 3.9 
Δ11q,14,21 10 Δ1Aq Δ1Aq: 6bp shift, occurs in all transcripts Δ1Aq,11q,14,21 Figure 3.12 
Δ3,9,10,11q 9 Δ1Aq 
Δ14Apf 
Δ1Aq: 6bp shift, occurs in all transcripts but one 
Δ14Ap: 7bp shift, occurs in some transcripts 
- Figure 3.13 
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3.4 Verification of isoforms 
The primers used for isoform verification were designed prior to the graphical analysis, 
so do not take into account possible splice acceptor or donor shifts. PCR was performed 
on cDNA with the goal of isolating the variant parts of the six isoforms identified in Table 
3.6 for Sanger sequencing. The full length BRCA1 PCR reaction was not performed. Many 
of the bands that appeared to be the correct size for the targeted isoform were revealed 
by Sanger sequencing to contain consecutive exons instead of the hypothesised 
alternatively spliced exons (data not shown). 
3.4.1 PCR and sequencing of predicted isoforms 
Two sets of primers (four primers in total) were initially designed for PCR reactions of 
each isoform. Junction primers were designed to span the exon/exon junctions at either 
side of each target isoform, while for the intron 21 insertion, primers were designed in 
the middle of the inserted region. Flanking primers were designed to encompass the 
whole isoform. Target product length was no less than 350bp. Additional primers were 
designed to increase the chances of successful Sanger sequencing for PCR products that 
were greater than 500bp. Primers used per isoform in PCR and sequencing are detailed 
in Table 3.7. 
The PCR method used in all cases was based on the standard protocol for products <3kb. 
For isoforms that were difficult to amplify and sequence additional primers were 
selected for testing from all primers designed throughout this project. The sequencing 
reactions were aligned to their predicted isoform references using the Geneious: Map 
to Reference function. Isoform Δ10-17 (Figure 3.15) and part of isoform 




Table 3.7: Isoform PCR and sequencing. 
                                                          
a Names of isoforms according to previous name because this experiment was designed prior to the graphical output analysis. 
b Primers used for PCR were also used for Sanger sequencing when applicable. 
c Sequencing primers were used when the predicted PCR product size was greater than 500bp, or when the verification process proved difficult. Additional or alternative primers 
were selected from all primers designed during this project to provide a greater chance of isoform confirmation. 
d Successfully confirmed. 










Δ10-17d (Junction)  BRCA1_9-18FJunc BRCA1_23RJunc del3R_Seq del11bF_Seq 408 YES 
Δ10-17 (Flanking)  del10-17FFlank del10-17RFlank - - 488 YES 
Δ11q19 (Junction)  BRCA1_11a-12FJunc BRCA1_18-20RJunc - - 1092 NO 
Δ11q19 (Flanking)  del11qF_Flank del19R_Flank del11qR_Seq del19F_Seq 1362 YES 
Δ3,11b (Junction)  BRCA1_2-5FJunc BRCA1_11a-11cRJunc del3R_Seq del11bF_Seq 685 YES 
Δ3,11b (Flanking)  del3F_Flank del11bR_Flank BRCA1_2-5FJunc 11a-11cRJunc 1117 YES 
Δ11q,21d (Junction)  BRCA1_11a-12FJunc BRCA1_ins21RJunc del19F_Seq del11qR_Seq 1361 YES 
Δ11q,21 (Flanking)  del11qF_Flank ins21_RFlank del11qR_Seq Ins21middleFwd 1666 YES 
Δ11q,14,21 (Junction)  BRCA1_11a-12FJunc BRCA1_20-22RJunc - - 1084 NO 
Δ11q,14,21 (Flanking)  del11qF_Flank del21R_Flank del11q+14R_Seq del21F_Seq 1349 YES 
Δ3,9,10,11q (Junction)  BRCA1_2-5FJunc BRCA1_11a-12RJunc - - 558 YES 






Figure 3.15: PCRs to confirm isoform Δ10-17.  
For all experiments, the standard protocol for products <3kb was used. The forward primer was BRCA1_9-
18FJunc and reverse primer was BRCA1_23RJunc. Annealing temperature was 64°C and extension time was 30 
seconds. A: 3µl of cDNA was used for the PCR reaction. 2µl of PCR product was loaded on a 1% gel. The band 
indicated was extracted by band stab. B: 1µl of extracted band solution from A was used in this PCR. 2µl of PCR 
product was loaded on a 2% gel. The band indicated was extracted by band stab. C: 1µl of extracted band solution 
from B was used in this PCR. 2µl of PCR product was loaded on a 2% gel. This reaction was Sanger sequenced. 
D: Geneious Map to Reference result of Sanger sequencing from C. Purple bar denotes position of exons 9 and 
18, green bar demonstrates the position of the BRCA1_9-18FJunc primer. The primer used for sequencing is 
noted beside each sequencing result. 
  





Figure 3.16: PCRs to confirm parts of isoform Δ1Aq,2p,11q,16p,21.  
For all experiments, the standard protocol for products <3kb was used. The forward primer was BRCA1_11a-
12FJunc and reverse primer was BRCA1_ins21RJunc. Annealing temperature was 64°C and extension time was 
1 minute. A: 3µl of cDNA was used for the PCR reaction. 2µl of PCR product was loaded on a 1% gel. The band 
indicated was extracted by band stab. B: 1µl of extracted band solution from A was used in this PCR. 2µl of PCR 
product was loaded on a 2% gel. This reaction was Sanger sequenced. C: Geneious: Map to Reference result of 
Sanger sequencing from B. Purple bar denotes positions of exon 11 (part a), exon 12, and exon 21. Pink bar 
denotes position of the intron 21 retention selected from published data. The primer used for sequencing is 
noted beside each sequencing result. 
 
 
Exon 11a Exon 12 
Exon 21 Intron 21 
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 Chapter 4: Discussion 
4.1 Summary of results 
This project has confirmed that the MinION nanopore sequencer can successfully read 
through cDNA of the long BRCA1 and BARD1 transcripts. In total, 52 full length BRCA1 
transcripts and 4835 full length BARD1 transcripts were sequenced. This research has 
also discovered 24 potential novel BRCA1 isoforms, and 18 potential novel BARD1 
isoforms. Of the six novel BRCA1 isoforms chosen for further analysis, five of these had 
acceptor or donor shifts present in some, if not all transcripts. Two of these were 
successfully Sanger sequenced, and the multiple exon deletions initially discovered 
were verified for isoforms Δ10-17 and Δ1Aq,2p,11q,21. 
During the course of this project, the full length BRCA1 transcript was amplified 
successfully through PCR, and a new data analysis pipeline for long transcript reads was 
developed. This pipeline uses the BLAT alignment program as its main component, and 
an additional program (Samcat.py) was developed in order to fully analyse each 
molecule’s sequence data.  
4.2 Sample preparation 
4.2.1 PCR and Sanger sequencing 
PCR of cDNA products was generally successful throughout this project. Short PCR for 
either end of BRCA1 generated PCR products that were relatively easy to isolate and 
Sanger sequence. BARD1 PCR consistently amplified the same set of bands, and was 
more difficult to isolate for Sanger sequencing. In order to gain a good representation 
of BARD1 products selected bands were extracted and sequenced. However, some of the 
final sample used for sequencing contained bands that had been amplified at least three 
times (using 35 cycles of amplification each time), so it was fortunate that the 
sequencing results turned out well enough that the sequence could be identified with 
ease.  
The primers to amplify the full transcript were designed to be within BRCA1 exons 1 
and 24, and BARD1 exons 1 and 11. This design does not allow the identification of 
alternative start or end transcription sites, and so will not identify transcripts such as 
BRCA1-IRIS, which has normal full length characteristics until it terminates shortly into 
intron 11. The focus during this project was whether this type of analysis was 
achievable with the MinION instead of trying to obtain a comprehensive survey of all 
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possible BRCA1 transcripts. Alternative transcription start and end sites is an area for 
further research now that the base method of analysis with the MinION has been 
established. 
4.2.2 Full length BRCA1 
Many different PCR conditions were used to amplify BRCA1 transcripts. These varied by 
annealing temperature and extension time, in most cases, and no single reaction 
produced completely consistent results. The stochastic variation in band patterns on 
electrophoresis of PCR reaction products indicated the possibility of random sampling 
during the process, particularly as this variation occurred even when carrying out 
multiple reactions using the same cDNA under the same conditions. Random sampling 
could have occurred either by the initial transcripts added to the sample, or in selection 
of available cDNA templates during the PCR reaction itself, particularly for those 
transcripts of smaller size. If it is the former, using the entire RNA sample from the cell 
line may ensure full isoform coverage, but if it is the latter, a pull-down approach may 
be a more reliable method, and may also be a more quantitative approach. It is likely 
that both possible explanations are contributing to the variation seen. This project was 
a proof-of-principle, and did not rely on generating the full range of isoforms produced 
by BRCA1, but this is an element that may be important for future work. The variation 
present in the long range PCR is testament to the many varied isoforms generated from 
the BRCA1 gene. 
4.2.3 MinION analysis 
The high molecular weight smear present in the BARD1 PCR samples (Figure 3.3A), 
became more prominent after the purification step (Figure 3.5). Presumably the smear 
resulted from nucleic acids of some sort. There was concern that it may affect the 
sequencing reaction, though there was enough data generated and it did not seem to 
have an effect on analyses. The low concentration of cDNA in the BRCA1 sample meant 
that it had to be pooled with BARD1 in MinION Sample 1, and many more BRCA1 PCR 
reactions were generated in order to have sufficient material for MinION Sample 2, 
which was solely composed of BRCA1 products. The difference in amount of BARD1 PCR 
products versus those of BRCA1 becomes strikingly apparent when the number of full 
length transcripts found for each are compared. Only 52 BRCA1 full length transcripts 
were identified, in contrast to 4835 full length BARD1 transcripts. Though the major 
cause for the large difference would be the amount of sample contributed for each gene, 
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another contributing factor is the long length of the full transcript from BRCA1. In the 
PCR reactions the smaller isoforms appeared to be more abundant than the full length, 
most of them had a molecular weight of 2300 to 2900 base pairs (Table 3.1). This is 
most likely due to the preferential amplification of smaller products during the PCR 
reaction, and is not a quantitative measure of relative abundance in the cell. 
Sample 2 was run on the same flow cell the day after Sample 1. The second run of the 
flow cell was not as good as the first (there were fewer pores available), but as we were 
reusing the same flow cell this was not unexpected. The washing step in between runs 
was performed twice, but as it is difficult to clean out completely there is still some 
BARD1 product appearing in the second sample. This contributes to the reasoning 
behind combining both data sets together for analysis, as there was no advantage in 
keeping the two separate. 
4.3 Data analysis 
The data analysis pipeline was developed using the entire dataset. Due to time 
constraints, a selection of six BRCA1 isoforms were chosen for further analysis as BRCA1 
was the main focus of this project. These isoforms were selected based on analysis of 
the BLAT tabular output, and further analysis was performed using the graphical format 
and Sanger sequencing. 
4.3.1 Iterative development of analysis pipeline 
Established methods of analysis for long read data have been optimised for genome 
sequences and unfortunately are not able to account for the long stretches of “deletions” 
that occur in transcript data. Established analysis methods for mRNA and cDNA data are 
based around splice junction detection, and are not suitable for detecting multiple exon 
alignments and potential intron retentions in one read.  Though there has been some 
research carried out on long read transcript data using the PacBio system I was unable 
to test these methods on my data set. The nanopore research that looked at alternative 
splice isoforms of the fly gene Dscam1 [142] seemed promising to inform my data 
analysis steps, but there were a number of differences between their research and the 
goal of this study which affected how the information was used. Firstly, the pattern of 
splicing in Dscam1 is very different to that of BRCA1. Dscam1 is divided into exon 
clusters instead of discrete exons, and within these clusters the exons are mutually 
exclusive. Bolisetty et. al., (2015) developed several LAST databases as references based 
on this clustering pattern to accommodate this pattern of splicing [142]. Bolisetty et. al., 
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(2015) also did not attempt to look for intronic variations in mRNA, which may have 
been due to the extensive splicing pattern already identified in this gene [142]. It was 
not clear how they had identified the nearly 8000 unique isoforms of the Dscam1 gene, 
and they do note that 3515 of these had a read depth of one. Three other genes, with 
simpler splicing patterns than Dscam1 and BRCA1, were looked at in this paper, with the 
longest isoform being close to 4kb, but the methods used were similar to those used for 
Dscam1 and were not able to inform the data analysis for BRCA1 and BARD1 in this 
research. 
The aim of this analysis was to establish a method that is able to map the cDNA reads 
back to their respective genes, and so be able to determine the exons present in each 
read. Ideally the method would be able to detect partial exon deletions and any intron 
retentions present as well, so ultimately a reference file was used that had the entire 
gene present. Many different methods of sequence analysis were trialled before the 
BLAT program was eventually settled on as the alignment that gave the best all-round 
results.  
Initially I began to work with the program LAST [147] because at the time it was a well-
used program within the MinION Access Program (MAP) community to work with 
MinION data [136, 142, 157-159]. However, it became apparent that although LAST 
appears to have specialised parameters for spliced reads it does not display the results 
very well (Figure 3.7). This may be due to the Multiple Alignment Format (MAF) that 
the program uses. Other programs gave similar results. BLAST [155], was excellent for 
giving the tabular summary that was needed to begin to group the results by isoform, 
though its parameters were too stringent for nanopore data. I decided to continue with 
BLAT’s more relaxed parameters and an output using the same tabular format as 
BLAST, rather than pursue experimentation with BLAST parameters to get a similar 
outcome. This way also guaranteed that the result would be the same as the graphical 
output of the BLAT alignment.  
The BLAT program required two different approaches to obtain a good overall view of 
the data. A summary of the isoforms present in the data set was required, therefore 
information on which exons were present in each read was needed. It was for this 
reason that the reference file was created with individual exon and intron sequences. 
The next step was to group them by which exons (and introns) were present. These 
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groups form the read depth of each isoform, required in order to identify which 
isoforms had high chances of being real.  
The tabular data analysis produced information as to whether each read aligned to each 
exon or intron reference sequence in a “yes or no” format, which does not give 
information about where exactly each read aligned in each reference. Therefore, 
visualisation of the results was important to determine alternative splice sites occurring 
in an isoform group, as demonstrated by the multiple acceptor and donor shifts 
described as present in BRCA1 transcripts in Table 1.1, and found by this research 
shown in Table 3.6. Upon initial examination of the graphical output, multiple reads 
were shown for each exon or intron reference sequence, however it was not feasible to 
view all the references together. It was this issue that prompted the development of the 
Samcat.py program. In order to properly analyse each isoform, the .sam files belonging 
to each group identified in the tabular analysis were manually extracted from the output 
of Samcat.py, and inspected individually in IGV. 
Shorter exons were more susceptible to changes in alignment parameters across all 
programs including BLAT. When more stringent parameters were applied there 
appeared to be a loss in the number of exons that registered an alignment, and often the 
shorter exons were the first to be lost. Using looser alignment parameters allowed more 
exons to be mapped to each read. This is highly likely to be the result of the high error 
rate of the MinION, as in shorter exons there is less chance of a good alignment 
occurring, resulting in these matches being discarded by most programs and default 
parameters. The shortest exon present in BRCA1 is exon 19, and because this was rarely 
missing in the final data set of isoforms I believe these BLAT alignment parameters are 
appropriate for this data. 
4.3.2 R and Excel manipulation 
Most of my tabular analysis was carried out in the program Excel. The statistical 
program R was necessary for the initial step of obtaining one line of data per read in 
order to open the smaller file in Excel for subsequent analysis steps. Given time 
constraints I was not able to develop the entire process in R, though that would have 
been preferable. 
Ideally the reads would not have needed to be forced into a specified alignment the way 
they were, but it was the only way to easily obtain a summary of isoforms. The exon 
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references included the known outer spliced areas in general (such as the initial NAG 
splice site), so this is likely to minimise the risk of missing splice occurrences. This was 
an advantage to looking at such a well-studied gene, as the risk of missing identification 
of new splice events is minimal.  
During the Excel analysis, filtering steps were applied which significantly reduced the 
number of reads available for analysis. One of these steps was removing all the reads 
that did not contain both exons 1 and 24, as without these exons the information for the 
transcripts amplified in this study design is incomplete. These reads may have been 
generated by shearing and fragmentation of the DNA during the library preparation. 
4.3.3 Graphical format output and program development 
Initially a BLAT alignment was performed against a reference file containing the single 
gene sequence (i.e. not split up into the multi-fasta file). This did produce alignments in 
the graphical view, though they seemed to align indiscriminately to introns and exons 
alike. This method also meant that there were two different reference files used for the 
same alignment, which may introduce other issues. To attempt to rectify these 
problems, a graphical output was used with an identical reference and parameters as 
the tabular output, which retained alignment consistency. This graphical format output 
initially gave an alignment per exon/intron, and the only way to view which alignment 
belonged to which read was to hover the mouse over the bar showing in IGV. The 
program Samcat.py was created in response to this problem. The aim of the program 
was to concatenate the CIGAR string part of the .sam alignment file in order to create 
one line per read, as previously there were multiple lines per read corresponding to 
each reference alignment. To the best of my knowledge, there is no existing tool that is 
able to combine alignment data like this. 
Due to the version of psl2sam.pl program that was used for this study, the resulting .sam 
file did not contain any sequence information, which meant that though the Samcat.py 
program was therefore easier to make, it also reduces the ability to check that the final 
alignment output from Samcat.py is correct. This version also uses M to denote matches 
and mismatches instead of differentiating the two. This resulted in the graphic 
associated with these .sam files not distinguishing between matches and mismatches. 
This program went through iterative development in order to debug outliers in the data. 
The types of problems occurring during program development were mostly due to 
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reads that probably were not from BRCA1 or BARD1, and were aligning everywhere and 
in any direction. In the end the decision was made to remove reads that were causing 
an excessive number of problems from the final file. This made the program simpler and 
at the same time it became useful for filtering out undesired alignments. At this stage, 
the calculations involved in creating the program, and the program as a whole, have not 
been independently tested. However, there is confidence that the reads that are of good 
enough quality to give helpful information will make it through the filtering process 
inherent in the program‘s creation. 
The major disadvantage of splitting the reference up into multiple sequences is the 
alignment of bases at each end of the exon (or intron) that are identical to the bases at 
the end of adjacent exons. The intron 21 graphical alignment demonstrates this problem 
exceptionally well (Figure 3.9E). According to the graphical alignment, the first five 
bases of the intron retention are CACAG. When this portion of the graphical alignment 
was first being examined, the initial conclusion was that in contrast to the published 
intronic inclusion in this area, the intron 21 alignment was picking up an acceptor shift. 
On inspection of the exon 21 sequence, it was found that the last five bases of exon 21 
are also CACAG (data not shown). This section of the sequence has aligned twice due to 
the reference sequences being treated as separate alignments, which is important to 
remember when looking at Samcat.py generated graphical outputs. This phenomenon 
can also be seen in Δ16p occurring in the same isoform (Figure 3.9D), and is described 
in Table 3.6.  
In each isoform group investigated there was at least one read which had appeared to 
belong to the relevant group in the tabular data but did not match correctly in the 
graphical view. This was apparent due to some of the filtering capability of Samcat.py, 
and it demonstrates that the initial BLAT alignment to the multi-fasta reference file in 
the tabular format requires further investigation. 
Upon initial observation, there seemed to be many small splice acceptor/donor shifts in 
the graphical view. On closer inspection, however, these tended to occur in runs of 
bases, or “slippery” sequences, such as “GGGGG” or “AAAA” (data not shown), and 
appeared to have little to do with the more standard NAGNAG sites of such splice 
changes in the 5’ end of the exon alignment. Given the extent and type of error the 
MinION is currently prone to, many of these “shifts” are most likely errors of sequencing 
rather than real changes. This theory is supported by the observation that deletions 
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often occurred at runs of the same base as well. This gives rise to some uncertainty for 
the Δ14Ap alignment in isoform Δ3,9,10,11q (Figure 3.13B). There appears to be a 7bp 
shift, but as this is out of frame it is unlikely, and could possibly be representing a 9bp 
shift instead due to the alignment then beginning with “AA”. Exon 13 contains 
“AAAAAG” at the 3’ end, which could be confounding this alignment. This shift could also 
be the previously described 3 base pair shift at this position, and this area is not being 
sequenced properly. There is certainly something out of the ordinary occurring at the 
5’ end of exon 14, though the read depth is not enough to be confident about what it is 
exactly, and any conclusions are confounded both by MinION inaccuracy and the fact 
that the graphical output aligns identical bases at the edges of exons twice.  
On close examination of the exon alignment in the full length reads it was discovered 
that all reads were missing three bases from the 3’ end of exon 10 (Figure 3.14D). This 
follows a run of six “A” nucleotides which may have affected the electrical signal of the 
MinION and subsequent basecalling, especially given the 6-mer increments of 
sequencing. This change is unlikely to be biologically valid, especially considering this 
particular change has not been seen before. The multiple combinations of splice shifts 
apparent in reads that contain all exons is interesting, however, and is important to 
consider in the characterisation of BRCA1 and associated isoforms. If the variations seen 
occurring in the graphical data are correct, there may be many more isoforms with small 
variations that would be difficult to identify.  
4.4 Isoform Analysis 
Six BRCA1 isoforms were chosen for further analysis by Sanger sequencing. This 
selection was based on the tabular output prior to the completion of the methodology 
for the graphical analysis, and therefore focuses only on detecting whole exon skipping 
events. Only two isoforms went through successful PCR and sequencing. As the BRCA1 
PCR was so variable, isoform-specific PCR was performed on cDNA sample directly. In 
order to detect the smaller changes within exons found through graphical analysis, 
isoform-specific PCR perhaps should be performed as a nested PCR on BRCA1 amplified 
samples. The parts Δ11q and 21 were confirmed from isoform Δ1Aq,2p,11q,21, but 
the rest of the changes described for this particular isoform have not yet been verified.  
All the proposed splice shifts were checked using Human Splicing Finder version 3.0 
[160]. In most cases the prediction was identical to my data analysis, and in the rest the 
prediction was in the same area but slightly shifted by one or two bases (data not 
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shown). This may reflect errors either in the MinION or in the alignment, and will need 
to be further investigated.  
4.4.1 Functional significance 
The commonality in all six isoforms further investigated is the lack of either the entirety 
of exon 11 or a large portion of it. This was a common feature of most of the isoforms 
found in the initial tabular analysis. It may be partially due to the fact that PCR 
preferentially amplified isoforms lacking most of exon 11 because they were 
significantly smaller. The lack of the majority of exon 11 does have functional 
consequences however, as exon 11 contains nuclear localisation signals, 
phosphorylation sites, sites of interaction with other proteins, and has also been found 
to play a role in DNA repair mechanisms and cell cycle arrest. Isoforms lacking this 
region may produce proteins that will not be efficiently localised to the nucleus, which 
means they could have other effects in the cytoplasm [161, 162]. However, if all these 
isoforms begin translation at the normal start site in exon 2, then very soon after the 
skipping event translation will stop, as all of these skipping events other than Δ11q 
create stop codons either at the junction (in the case of Δ3), or very soon after the event. 
The intron retention encodes a stop codon 56 bases into the retained region. It is 
difficult to predict what effects all these changes will have on BRCA1 isoform function, 
though without the repair regions and phosphoprotein binding domains encoded in 
exon 11 and in later exons, it can be hypothesised that many of these isoforms may 
display oncogenic features similar to BRCA1-IRIS, which stops translation a short way 
into intron 11 and does not retain the rest of the transcript [60, 105, 106]. On the other 
hand, these transcripts may have an unknown regulatory function within the cell, or 
perhaps even undergo ribosomal “slipping” during translation and manage to get back 
in-frame, due to the many slippery sequences in BRCA1 exons such as those which the 
MinION also has trouble reading (described in Section 4.3).  
All complete exon skipping events of BRCA1 isoforms, the splice donor shifts Δ1Aq and 
Δ5q, and acceptor shift Δ2p, that have been identified in this work have been found 
previously [60]. The difference is that none of these changes have been described in the 
same transcript as those presented here. The fact that these changes have been 
previously identified increases the confidence that the results of this study are correct. 
The other splice shifts identified by the graphical analysis will need further verification 
to be certain they are correct. Finding events such as these was an unexpected result 
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from the MinION during this study, and the number of these small shifts observed 
demonstrates the complexity of splicing at the BRCA1 locus. These smaller variations 
may not cause as great a difference in functional outcome compared to the larger exon 
skipping events, but they may still have cellular effects which can only be explained by 
tiny changes in transcripts. Additionally, these multiple splice shifts observed in a single 
transcript have important implications for determining the clinical relevance of splicing 
associated variants. For example, a single shift or exon skipping event may be 
interpreted as an in-frame deletion which is non-deleterious, but other events in the 
same molecule may have an out-of-frame effect, changing the functional outcome. 
Alternatively spliced transcripts previously identified as being low risk for disease 
might actually be high risk, and vice versa. These are possibilities that may now need to 
be considered when assessing splicing changes associated with BRCA1 variants. 
4.5 Limitations of this work 
One limitation of the transcript analysis in this thesis was that it was not quantitative 
due to the differential amplification nature of PCR. This research demonstrates that PCR 
amplifies a random selection of cDNA molecules. Perhaps a more quantitative study 
would use a pull-down approach to isolating cDNA, such as using gene specific 
biotinylated oligonucleotides and streptavidin beads to capture the target transcripts 
before sequencing on the MinION. There would need to be a very large amount of 
starting RNA to work with to ensure as many BRCA1 isoforms as possible were collected, 
and a final amount of 1µg of cDNA to go into MinION library preparation. 
Nonsense-mediated decay (NMD) plays a biological role in cell processes deciding 
which mRNA molecules are destroyed. NMD may vary in function between cell types. It 
is important to be aware that other cells, such as those in the breast tissue, may have 
NMD that functions differently to that of a lymphoblastoid cell line. Isoforms found in 
this NMD-treated cell line may not be detected in an untreated cell line, but they may be 
a normally expressed isoform in the breast. To test this would require analysis to be 
carried out on normal breast tissue, and this was not possible during this study. 
The MinION read depth was enough to gain an idea of the isoforms present, but due to 
the current error rate of the MinION, ideally a higher read depth would increase the 
confidence of the results, particularly of those splice shift events that have not been 
identified before. There was on average about seven reads per isoform group in the 
graphical output that actually matched everywhere predicted in the tabular output, so 
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small differences identified, such as 2-3 base acceptor/donor shifts, are much less 
certain than the larger ones of 9-12 bases, especially if they only occurred in some of 
the reads. Nevertheless, two of the identified isoforms have had a number of their non-
contiguous splicing events confirmed in this study. 
Error correction is available for nanopore data, however this is based on an averaging 
of the reads which is not suitable for this research. Error correction on isoform groups 
was considered prior to isoform groups being identified, but was not plausible due to 
the low read depth of each isoform, and may have masked the smaller changes occurring 
in some of the reads. 
In previous work on cDNA with MinION sequencing, the rate of template switching was 
quantified [142]. This may have occurred during PCR cycles in BRCA1 and BARD1 
samples, however, due to limited time and resources I was not able to test whether 
template switching of strands during PCR was occurring in my samples. This paper 
found that the rate of template switching in the Drosophila gene Dscam1 was high with 
30 cycles of PCR [142], while I needed to use 35 cycles of PCR in order to gain enough 
BRCA1 molecules to visualise on an agarose gel. There was a large difference in size of 
our respective amplicons, the size of the Dscam1 amplicon was 1.8kb whereas BRCA1 
and BARD1 were 5.8kb and 2.0kb respectively. Template switching is specific to each 
reaction depending on the molecule and primers, and would have been of concern for 
Dscam1 in particular because of the immense variability in possible exons per 
transcript, but is not so crucial for the amplification of the less variable BRCA1 or BARD1 
genes. 
Improvements to this project could include: where at all possible mixing the samples 
containing cDNA by inversion rather than pipetting to reduce amount of DNA shearing, 
generating significantly more BRCA1 PCR product to run on the MinION (enough to be 
able to run it independently) in order to have greater read depth per isoform, and 




4.6 Conclusion and implications of this research 
This research aimed to determine the viability of using the long read MinION nanopore 
sequencer to help fill the gap in knowledge of the alternative splice transcripts 
generated by BRCA1 and BARD1. During the course of this study, successful long range 
BRCA1 PCR was performed to amplify the entire full length transcript, along with many 
isoforms, and a bioinformatic pipeline using the BLAT aligner has been developed in 
order to analyse long transcript reads that span multiple exons and introns. This 
analysis has also been able to detect both large and small splice shifts in these transcript 
reads. A new program to deal with the multi-reference graphical output of the alignment 
was also developed. Overall, this project has been successful in demonstrating the 
capability of the MinION device to identify these isoforms, and in demonstrating how to 
use the necessary tools to analyse the sequence data. 
Improvements to the data analysis pipeline could be made with a tool for aligning whole 
gene reference sequences but with the ability to assign regions and get a summary of 
this data, effectively combining the two branches of my data analysis pipeline together. 
The complexity of splicing at the BRCA1 locus is revealed in this research to be much 
greater than previously speculated, and this may also be true for many other genes with 
alternative splicing characteristics. This research opens the door for a more complete 
annotation and understanding of alternative splicing in mammals. More immediately, it 
will greatly increase the confidence of BRCA1 and BARD1 isoform prediction, furthering 
the understanding of these critical tumour suppressor genes, and may lead to 
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Appendix A: Positions of primers described in Table 2.2 
A.1  Isoform Δ10-17: 
 
Figure A.1: Figure of primer positions used for amplification and sequencing of isoform Δ10-17.  
Figure generated using Geneious® 9.1.5, Biomatters Ltd. 
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A.2 Isoform Δ11q21 
 
Figure A.2: Figure of primer positions used for amplification and sequencing of isoform Δ11q21.  





A.3 Isoform Δ3,11Δ3110 
 
Figure A.3: Figure of primer positions used for amplification and sequencing of isoform Δ3,11Δ3110.  
Figure generated using Geneious® 9.1.5, Biomatters Ltd. 
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A.4 Isoform Δ11q,14,21 
 






Figure A.4: Figure of primer positions used for amplification and sequencing of isoform Δ11q,14,21.  






A.5 Isoform Δ3,9,10,11q 
 
Figure A.5: Figure of primer positions used for amplification and sequencing of isoform Δ3,9,10,11q.  
Figure generated using Geneious® 9.1.5, Biomatters Ltd. 
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A.6 Isoform Δ11q,19 
 
Figure A.6: Figure of primer positions used for amplification and sequencing of isoform Δ11q,19.  





Appendix B: Pre-Amplicon protocol bead clean-up 
 
Materials: 
 MagBio Ampclean beads. 
 Make fresh 80% ethanol 
 Using 4 KingFisher 96-well plates - every second well 
o Plate 1: DNA plate 
o Plate 2: Wash 1 
o Plate 3: Wash 2 
o Plate 4: Eluent (ddH2O) 




1. Measure volume of DNA, and add to the DNA plate 
2. Add 1x volume of vortexed beads (e.g. for 80ul of sample use 80ul of beads). Use higher 
concentrations for smaller sizes. 
3. Mix up and down with the empty KingFisher tip 
4. Add 200ul 80% ethanol to Wash 1 and Wash 2 in the appropriate wells 
5. Add KingFisher magnetic  head to DNA plate (in the tip used before), and wait for the 
supernatant to clear. Should be done within 5 mins. 
6. Transfer magnetic head carefully into Wash 1 
7. Transfer it again into Wash 2 
8. Add appropriate amount of water to Eluent plate, typically 20-25ul. Depends how 
concentrated you want it. 
9. Remove head from Wash 2 and air dry, want to let the ethanol evaporate but not have the 
beads so dry they crack. Watch so it doesn't get too dry, look for shinyness. 
10. Now add the head to the Eluent plate, then remove the magnet, leaving the tip plate in 
place. 
11. Mix the tips up and down and leave for ~5mins to elute. 
12. Put the magnetic head back and wait for the solution to clear - want to get all the beads. 
Remove the head and tips 
13. Transfer the Eluate to Lo-bind tubes. Remember the new volume is 20-25ul. 
14. Measure on Nanodrop/Qubit. 
 




Appendix C: Amplicon library preparation protocol R9 Version 
1. Library Preparation 
a. Overview of the Nanopore Sequencing protocol 
 
Introduction to the Nanopore Sequencing Kit 
  
IMPORTANT:  
The products in use with this Experiment CompanION  
This protocol should only be used in combination with:  
 Nanopore Sequencing Kit SQK-NSK007 (R9 Version) 
 MinION Flow cells with the code FLO-MIN104 (R9 Version)  
 MinKNOW scripts with the prefix NC_ and ending in FLO_MIN104 
 Workflows for SQK-NSK007  
If using Expansion Packs all are compatible with the exception of the Native Barcoding Kit where the 
product code EXP-NBD02 is required. 
  
Introduction to the Nanopore Sequencing Kit  
 The Nanopore Sequencing Kit is designed to prepare genomic, amplicon and cDNA, with or 
without barcoding, for sequencing on the Oxford Nanopore MinION™. 
 The kit features an adapter which is compatible with the Oxford Nanopore motor protein and 
which must be ligated onto end-repaired and A-tailed fragments. The workflow for nanopore 
sequencing consists of steps for template preparation and then steps required for adapter 
ligation. 
 
Figure NSKS: Schematic of the Nanopore Sequencing Kit protocol.  
The steps in the box are carried out using the Nanopore Sequencing Kit reagents. The input 




Storage instructions for the Nanopore Sequencing Kit (SQK-NSK007)  
On receipt the kit should be stored at -20 °C. 
  
IMPORTANT:  
To keep freeze/thawing to a minimum, it is advisable to thaw only the barcodes and adapters 
required for the particular experiment. The kit should be stored at -20 °C when not in use. Keep on 
ice when thawed.  
  
b. Nanopore sequencing kit contents 
 
Reagents provided in the kit 
  
Nanopore Sequencing Kit (SQK-NSK007)  
The kit contains the reagents required to prepare a DNA library for the MinION. There are 
sufficient reagents for preparing six libraries for loading into the MinION Flow Cell. 
 
The reagents are multi-use tubes. Freeze/thaw of the RBF1, Hairpin Adapter, Adapter Mix and 
Hairpin Tether should be kept to a minimum, so it is advisable to only thaw the tubes required on 
the particular day. RBF1 can be stored at 4 °C if carrying out multiple loadings. Each RBF1 tube 
contains enough buffer for priming the flow cell and preparing the library for loading. 
  
Kit contents  
Contents Colour No. of tubes 
Adapter Mix (AMX) green 3 
HP Adapter (HPA) purple 1 
HP Tether (HPT) purple stripes 1 
Lambda DNA (LMD) at 50 ng/µl yellow 1 
DNA CS (DCS) yellow stripes 1 
Elution Buffer (ELB) black 1 
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Bead Binding Buffer (BBB) red stripes 2 
Running Buffer with Fuel1 (RBF1) red 6 
Primer Mix (PRM) grey 1 




Thoroughly mix the contents of each tube by inversion (vortexing or pipetting for Running Buffer), 
and spin down very briefly before pipetting to ensure the contents of the tube can be aspirated 




End-repair and dA-tail of double-stranded DNA fragments (~50 minutes) 
  
Materials  
 DNA CS  
 1 µg amplicon DNA in 45 µl nuclease-free water  
Consumables  
 NEBNext End repair / dA-tailing Module (E7546)  
 Freshly prepared 70% ethanol in nuclease-free water  
 1.5 ml Eppendorf DNA LoBind tubes  
 Nuclease-free water  
 Agencourt AMPure XP beads 
Equipment  
 Thermal cycler at 20 °C and 65 °C  
 Magnetic rack  
 Hula mixer (gentle rotator mixer)  
 Vortex mixer  
 Ice bucket with ice  
Optional Equipment  
 QuBit fluorimeter (or equivalent for QC check)  
  
1. Perform end repair and dA-tailing of fragmented DNA as follows: 
Mix the following reagents in a 1.5 ml Eppendorf DNA LoBind tube: 
Reagent Volume 
~1 µg DNA (fragmented genomic DNA, amplicon or cDNA) 45 µl 
Ultra II End-prep reaction buffer 7 µl 
Ultra II End-prep enzyme mix 3 µl 
DNA CS 5 µl 
Total 60 µl 
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If using the barcoding approach the pooled input DNA should be ~1 µg in 45 µl, whether 
genomic, amplicon or cDNA. 
2. Mix gently by inversion and spin down. 
3. Transfer the sample to a 0.2 ml PCR tube, and incubate for 5 minutes at 20 °C and 5 minutes at 
65 °C using the thermal cycler. 
If condensation is observed in the tube after the thermocycling, briefly spin down the tube 
contents in a microfuge. 
4. Resuspend AMPure XP beads by vortexing. 
5. Transfer the sample to a 1.5 ml DNA LoBind Eppendorf tube. 
6. Add 60 µl of resuspended AMPure XP beads to the end-prep reaction and mix by pipetting. 
7. Incubate on a rotator mixer (Hula mixer) for 5 minutes at room temperature. 
8. Prepare 500 μl of fresh 70% ethanol in nuclease-free water. 
9. Spin down the sample and pellet on a magnet. Leaving the tube on the magnet, pipette off the 
supernatant. 
10. Keep on magnet, wash beads with 200 µl of freshly prepared 70% ethanol without disturbing 
the pellet. Remove the 70% ethanol using a pipette and discard. Repeat. 
11. Spin down and replace on magnet to collect and pipette off any residual 70% ethanol. Briefly 
allow to dry. 
12. Remove the tube from the magnetic rack and resuspend pellet in 31 µl nuclease-free water. 
Incubate for 2 minutes at room temperature. 
13. Pellet beads on magnet until the eluate is clear and colourless. 
14. Remove and retain 31 µl of eluate into a clean 1.5 ml Eppendorf DNA LoBind tube. 
15. Quantify 1 µl of end-prepped DNA using a QuBit fluorimeter - recovery aim > 700 ng. 
 
End of Step:  
Take forward approximately 700 ng of end-prepped DNA in 30 µl into adapter ligation. 
  
  
d. Adapter Ligation 
 
Addition of adapters and the Tether (~25 minutes) 
  
Materials  
 Bead Binding Buffer (BBB)  
 Elution Buffer (ELB)  
 HP Adapter (HPA)  
 HP Tether (HPT)  
 Adapter Mix (AMX)  
Consumables  
 NEB Blunt/TA Ligase Master Mix (M0367)  
 1.5 ml Eppendorf DNA LoBind tubes  
 Nuclease-free water  
Equipment  
 Microfuge  





Fragment size and adapter ligation  
The amount of adapter has been optimised for fragment sizes greater or equal to 8 kb. If the 
fragments are generally smaller than 3 kb adjustments should be made to use 0.2 pmoles of DNA in 
the adapter ligation step. 
  
1. Check the content of each tube is clear of any precipitate and are thoroughly mixed before 
setting up the reaction. 
 Mix the contents of each tube by inversion 
 Check that there is no precipitates present (DTT in the Blunt/TA Master Mix can 
sometimes form a precipitate) 
 Spin down briefly before accurately pipetting the contents in the reaction 
2. Taking the end-prepped DNA, perform adapter ligation as follows, mixing by inversion between 
each sequential addition. 
Reagent Volume 
End-prepped DNA 30 µl 
Nuclease-free water 8 µl 
Adapter Mix 10 µl 
HP Adapter 2 µl 
Blunt/TA Ligation Master Mix 50 µl 
Total 100 µl 
3. Mix gently by inversion and spin down. 
4. Incubate the reaction for 10 minutes at room temperature. 
5. Add 1 µl HP Tether. 
6. Mix gently by inversion and spin down. 
7. Incubate the reaction for 10 minutes at room temperature. 
8. Prepare MyOne C1 beads for the purification of the DNA library during this incubation. 
  
End of Step:  
Adapted and tethered DNA library.  
The adapted and tethered DNA library is now ready to be purified prior to loading into the MinION 






e. MyOne C1 bead buffer exchange 
 
Shipping buffer exchanged for Bead Binding Buffer (~20 minutes) 
  
Materials  
 Bead Binding Buffer (BBB)  
Consumables  
 MyOne C1 Streptavidin beads  
 1.5 ml Eppendorf DNA LoBind tubes 
Equipment  
 Magnetic rack  
 Vortex mixer  
 Microfuge  
 Ice bucket with ice  
  
1. Vortex MyOne beads and transfer 50 µl to a clean 1.5 ml Eppendorf DNA LoBind tube. 
2. Pellet beads on magnet until the eluate is clear and colourless. 
3. Pipette off the supernatant and discard. Retain the bead pellet. 
 Pellet the beads on the magnet until the supernatant is clear and colourless 
 Avoid removing the supernatant too early as this will cause loss of the beads available for 
purification. You can check whether all the beads have pelleted by looking inside the tube 
from the top down. 
4. Add 100 µl Bead Binding Buffer to the pelleted beads, vortex until homogeneous, pellet the 
beads on the magnet. Pipette off and discard the supernatant. Repeat. 
 This is a wash step which needs to be carried out twice 
 Add 100 µl Bead Binding Buffer to the pelleted beads 
 Resuspend beads by vortexing 
 Place the tube on the magnet and allow the pellet  
 Discard supernatant 
5. Add 100 µl Bead Binding Buffer to the pelleted washed beads. Resuspend beads by vortexing. 
  
End of Step: 
These are the washed beads required for the DNA library purification. 
  
f. Library purification 
Purification of the adapted and tethered DNA library (~10 minutes) 
  
Materials  
 Bead Binding Buffer (BBB)  
Consumables  
 MyOne C1 Streptavidin beads in Bead Binding Buffer (washed beads)  
Equipment  
 Magnetic rack  




1. Add 100 µl of washed MyOne C1 beads to the adapted and tethered DNA reaction and carefully 
mix by pipetting. 
Library purification demo 
2. Incubate on a rotator mixer (Hula mixer) for 5 minutes at room temperature. 
Mixing washed MyOne C1 beads and DNA library  
The mixing is gentle but enough for the DNA fragments and the beads to come into contact 
with each other. 
3. Place on magnetic rack, allow beads to pellet and pipette off supernatant. 
4. Wash the pellet by resuspending in 150 µl Bead Binding Buffer by pipetting. Pellet on magnet, 
pipette off and discard the supernatant when clear and colourless. Repeat. 
5. Close tube lid, spin down, replace on magnet for 1-2 minutes, open lid and pipette off any 
residual Bead Binding Buffer. 
  
End of Step: 
The DNA library is bound to the beads and ready for elution.  
  
g. Elution of library 
 
Elution of the library and a final QC check (~15 minutes) 
  
Materials  
 Elution Buffer (ELB)  
Consumables  
 1.5 ml Eppendorf DNA LoBind tubes 
  
1. Resuspend pellet in 25 µl of Elution Buffer by pipetting up and down. Incubate for 10 minutes 
at 37 °C. 
2. Pellet beads on magnet until the eluate is clear and colourless. 
3. Remove and retain 25 µl of eluate into a clean 1.5 ml Eppendorf DNA LoBind tube. 
 Remove and retain the eluate which contains the DNA library in a clean 1.5 ml Eppendorf 
DNA LoBind tube 
 Dispose of the pelleted beads 
4. Place the tube of library on ice until required for library loading. 
  
Quantify 1 µl of fragmented and repaired DNA using a QuBit fluorimeter - total recovery aim ~ 250 
ng.  
  
End of Step: 
Aliquots of the prepared library are used for loading into the MinION Flow Cell. This library is called 





2. Preparing to load a library 
a. Priming the MinION Flow Cell 
 
Priming of the sensory array in the flow cell (~20 minutes) 
  
Materials  
 Running Buffer with Fuel Mix 1 (RBF1)  
Consumables  
 MinION Flow Cell  
Equipment  
 MinION Mk I  
  
IMPORTANT:  
Thoroughly mix the contents of the RBF1 tube by vortexing or pipetting, and spin down briefly. 
  
1. Flip back the MinION lid and slide the sample port cover clockwise to that the sample port is 
visible. 
Priming and loading a library into a flow cell  
 
Figure PFOP: Opening the sample port by rotating the sample port cover. Ensure that the 
sample port cover is fully opened (a 90 ° clockwise turn). 
2. After opening the sample port, check for small bubble under the cover. Draw back a small 
volume to remove any bubble (a few µls). Visually check that there is continuous buffer from 
the sample port across the sensor array.  
This image shows the MinION Mk I Flow Cell. 
 
Figure PFLM: Labelled view of the MinION Flow Cell. 




RBF1 500 µl 
Nuclease-free water 500 µl 
Total 1000 µl 
4. Load 500 µl of the priming mix into the flow cell and wait 10 minutes, avoiding the introduction 
of air bubbles. Repeat. 
  
End of Step:  
The flow cell is now ready for the library to be loaded.  
  
3. Loading a library 
Preparing and loading the library into the flow cell (~5 minutes) 
  
Materials  
 Adapted and tethered DNA library (Pre-sequencing Mix)  
 Running Buffer with Fuel Mix 1 (RBF1)  
Consumables  
 Nuclease-free water  
 1.5 ml Eppendorf DNA LoBind tubes  
  
1. Prepare the library for loading as follows: 
Reagent Volume 
RBF1 75 µl 
Nuclease-free water 63 µl 
Adapted and tethered library 12 µl 
Total 150 µl 
2. Mix gently by inversion and spin down. 
3. Using a Gilson P-1000, load 150 µl of the prepared library into the flow cell keeping the pipette 
vertical. 
 
4. Close the sample port with the cover and replace the MinION lid. 
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D.2 Combine reads for full analysis 
Objective: To combine all BRCARD1 reads, 2D only, and 1D reads from the fail folder, and also combine 
with the same of the BRCA1 folder. 
Want a copy of each of BRCARD1D.fasta, BRCARD2D.fasta, BRCA11D.fasta and BRCA12D.fasta in 
/media/projects/Lucy/Reads/final_group 
  
#Make the fasta files from MinION reads 
poretools fasta --type 2D /media/gsfl/MinION/BRCARD_1/pass > 
BRCARD2D.fasta 
poretools fasta --type all /media/gsfl/MinION/BRCARD_1/fail > 
BRCARD1D.fasta 
poretools fasta --type 2D /media/gsfl/MinION/BRCA1/pass > BRCA12D.fasta 
poretools fasta --type all /media/gsfl/MinION/BRCA1/fail > BRCA11D.fasta 
#Concatenate the files to create a file with all the reads contained 
cat BRCARD2D.fasta BRCARD1D.fasta BRCA12D.fasta BRCA11D.fasta > all.fasta 
#Number the files 
awk '/>/ {$0 = ">" ++n} 1' all.fasta > allnum.fasta  
awk 'NR % 2 != 0' all.fasta > alltrackd.txt 
#Changed names manually at this stage: all.fasta to all_orig.fasta to 
retain the original file, then allnum.fasta to all.fasta for general use. 
  
D.3 BLAT analysis with parameters from UCSC website 
Objective: To align the reads to my BRCARD reference with both exons and introns in separate 
sequence lines, including exon 11 split into 3 parts. This reference is called 
BRCARD1genetranscript.fasta and is found in the Y drive.  
BLAT commands <file://Y:\Lucy\Data\scripts\BLAT.sh> 
#Do BLAT alignment 
#Usage: /media/projects/Lucy/programs/blatSuite/blat [ref.fasta] 




cp /media/gsfl/Lucy/Data/Reads/all.fasta all.fasta 
#pslx file 
/media/projects/Lucy/programs/blatSuite/blat BRCARD1genetranscript.fasta 




all.fasta -stepSize=5 -repMatch=2253 -minScore=0 -minIdentity=0 -
out=blast8 allgenet.blast8 
  
#Convert pslx file to sam file and samtools process - need to put in the 
header separately (samtools view -ht) 
/media/projects/Lucy/programs/psl2sam.pl allgenet.pslx > allgenet.sam 
samtools faidx BRCARD1genetranscript.fasta 
samtools view -ht BRCARD1genetranscript.fasta.fai allgenet.sam 
samtools view -T BRCARD1genetranscript.fasta -bS allgenet.sam | samtools 
sort - allgenet.sorted 




D.4 Separate BRCA1 and BARD1 out into different files 
Python script to separate out BRCA1 and BARD1 alignments from BRCARD1 references: 
 <file://Y:\Lucy\Data\scripts\Isoforms.py> 
Note: green means fields to change depending on what I want. (Name of file, and BRCA1/BARD1) 
import csv 
  
#opens the file produced by blast8 - make sure extension is .txt 
with open("allgenet.blast8", 'r') as tsvin: 
    allexonstab = csv.reader(tsvin, delimiter='\t') 
    allexons = list(allexonstab) 
    tsvin.close() 
  
#extract all lines containing the gene it's referenced to. Change gene 
names appropriately 
allexonsGENE = [] 
for line in allexons: 
    for i in range(0, len(line)): 
        if "BRCA1" in line[i]: 
            allexonsGENE.append(line) 
  
file = open("allgenetBrca1.csv", "w") 
for item in allexonsGENE: 
    file.write("%s\n" % ",".join(item)) 
file.close() 
 
D.5 R script 
Objective: R script to get all exon hits on one line per read: 
<file://Y:\Lucy\Data\scripts\R_manipulation.R> 
Note: green means fields to change depending on what I want. 
#import from the split file python made 
#Add header to file 
colnames(allgenetBrca1) = c("readname", "ref", "%identity", 
"alignment_length", "mismatches", "gap_opens", "query_start", 
"query_end", "subject_start", "subject_end", "evalue", "bit_score") 
  
#Expand ref column into matches per exon 
refCountsBRCA1 = dcast(allgenetBrca1, readname~ref) 
  





D.6 Excel methods 
Excel methods for each set, BARD1 and BRCA1: 
1. Import table and organise Exon columns into the right order, then Introns following that 
immediately. Copy sheet twice, labelled FullLengthTable and IsoformsTable. 
2. FullLengthTable: To get the right number of full length reads, changed all 0's to 1's in both Exon 
1 and Exon 11/24 columns (BARD1/BRCA1). Copy worksheet, name copy to CatFullLength (short 
for concatenate). Insert a column break between Exon block and intron block in both sheets. 
3. CatFullLength: Above the reference names put exon number followed by comma (when 
concatenated for easy reading), e.g. "1,". Use lowercase letters for the introns (e.g. a, b, c, etc.) 
Use this "if" statement for each cell in the exon block: IF(FullLengthTable!B3=0, 
CatFullLength!B$1, ""). This states that if the corresponding cell in the FullLengthTable is 0, put 
the contents of what is above the reference into the cell that the statement is in. Expand so 





4. CatFullLength:  Do something similar for the intron block. If statement: 
IF(IsoformsTable!AB3=0,"",CatIsoforms!AB$1). This states that if the corresponding cell in the 
FullLengthTable is 0, leave the cell blank, otherwise put the contents of what is above the 
reference into the cell that the statement is in. Expand so formula covers all cells in table. This 
will result in the cell being filled by the letter corresponding to the intron that is included in the 
isoform.  
5. CatFullLength: At end of Exon references, concatenate all the cells in the row to get a list of 
missing exons, using the CONCATENATE function. Name this column "DelExons". Do the same 
for the intron block, naming it InsIntron. In the column after this, use the CONCATENATE 
function again on both the DelExons column and InsIntron column to get a list of both deleted 
exons and inserted introns. Label it DelExons+InsIntrons. 
6. SortedFullLength: Select the two columns containing row names and concatenated reference 
names, copy them into a new sheet called SortedFullLength. Out of these two columns make a 
pivot table. In the PivotTable Fields toolbar drag "DelExons+InsIntrons" into the ROWS box, and 
"readname" into the VALUES box. Ensure the readnames is set to "Count of readnames" (not 
sum). 
7. SortedFullLength: Sort "count of readname" column largest to smallest. Find the number that 
corresponds to the empty cell under Row Names, and this is the correct number of full length 
reads from this dataset. 
8. IsoformsTable: Get rid of reads that have a 0 at either the first or last exon by sorting the table 
by the first exon column smallest to largest, deleting all rows with 0 in this column, and repeat 
with the last exon column. Copy worksheet, name copy to CatFullLength (short for concatenate). 
Insert a column break between Exon block and intron block in both sheets. 
9. Repeat steps 3, 4, 5 and 6 but with name Isoforms instead of FullLength. 
10. SortedIsoforms: Sort "count of readname" column largest to smallest. This is the list of isoforms 
present in the data. 
  














Alignment.py: Takes a reference file and an alignment file 
in SAM format and combines each set of reads into a single 
cigar string 
""" 
# This program requires an additional comma separated file containing the 
reference names used to generate the 
# SAM file, and the associated size of the reference in base pairs. The Reference 
file must be in order. 
# eg. Reference,96 
# This program works by looking first at all the alignments occurring with the 
same reference and the same read, 
# concatenating these CIGAR strings, then looking at the alignments occurring for 
each reference within the same read 
# and concatenating these CIGAR strings in the order presented in the additional 
reference file. 
 
__author__ = "Cade Picard" 
 
 
# Opens the file containing the reference name used and the size of the reference 
in base pairs, in csv format. 
# Returns a list of lists of the references e.g. 
[[BRCA1_Exon1,213],[BRCA1_Intron1,1155]] 
def get_references(): 
   with open("RefSizes.csv") as file: 
      refReader = csv.reader(file) 
      references = list(refReader) 
      file.close() 
   return references 
 
 
# Returns a dictionary of the reference file given 
# Key: exon name 
# Value: reference length 
def generate_reference_dict(references): 
   ref = {} 
   for i in range(0, len(references)): 
      ref[references[i][0]] = [references[i][1], i] 
   return ref 
 
 
# Finds all rows pertaining to a single read, removes them from the list of all 
reads. Returns 2 lists of lists. 
# Output = rows pertaining to the read 
# Rows = rest of the remaining reads from the file 
def find_all_rows(readNumber, rows): 
   output = [] 
   indexs = [] 
 
   # Find all the rows for the read 
   for i in range(0, len(rows)): 
      if int(rows[i][0]) == int(readNumber): 
         output.append(rows[i]) 
         # Add index to the indexs array for deletion 
         indexs.append(i) 
   # Reverse indexs array to stop the deletion of the wrong rows 
   indexs.reverse() 
   # Delete the rows pertaining to the read in reverse order 
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   for index in indexs: 
      del rows[index] 
   return output, rows 
 
 
# Sort the rows by the order of the references in the reference csv file. Returns 
sorted list 
# Output = sorted list of all the rows for the read 
def sort_rows(rows, references): 
   output = [] 
 
   # Sorts the reads by the name of the reference in the order specified in the 
reference file 
   for i in range(0, len(references)): 
      for j in range(0, len(rows)): 
         if references[i][0] == rows[j][2]: 
            output.append(rows[j]) 
 
   # Sorts references with the same name by the references start value in 
ascending order 
   k = 0 
   while k < len(output) - 1: 
      if output[k][2] == output[k + 1][2]: 
         if int(output[k][3]) > int(output[k + 1][3]): 
            temp = output[k] 
            output[k] = output[k + 1] 
            output[k + 1] = temp 
            k = 0 
      k += 1 
   return output 
 
 
# Find all numbers associated with M, =, and X in a CIGAR string. Total them up 
and return the total 
def count_matches(cigarString): 
   total = 0 
   matchM = re.findall(r'(\d+)M', cigarString) 
   matchEquals = re.findall(r'(\d+)=', cigarString) 
   matchX = re.findall(r'(\d+)X', cigarString) 
   for num in matchM: 
      total += int(num) 
   for num in matchEquals: 
      total += int(num) 
   for num in matchX: 
      total += int(num) 
   return total 
 
 
# Find all numbers associated with I in a CIGAR string. Total them up and return 
the total 
def count_insertions(cigarString): 
   total = 0 
   matchI = re.findall(r'(\d+)I', cigarString) 
   for num in matchI: 
      total += int(num) 
   return total 
 
 
# Find all numbers associated with D in a CIGAR string. Total them up and return 
the total 
def count_deletions(cigarString): 
   total = 0 
   matchD = re.findall(r'(\d+)D', cigarString) 
   for num in matchD: 
      total += int(num) 





# Calculate the length of the gap from the previous aligned reference end to the 
current aligned reference start 
def calculate_length(reference, stopPoint, startPoint = 0): 
   total = 0 
   for i in range(startPoint, stopPoint): 
      total += int(reference[i][1]) 
   return total 
 
 
# Combining the CIGAR string for the first row with the CIGAR string for the 
second row within 
# alignments of the same read. 
# firstCigar = The cigar string of the first row to be combined 
# referenceLength1 = The length of the reference that is associated with the 
first row 
# referenceStart1 = The start position of the alignment in the first row 
# secondCigar = The cigar string of the second row to be combined 
# gapLength = The length of the gap from the previous aligned reference end to 
the current aligned reference start. 
#          This is how the program accounts for Intron gaps and Exon skipping. 
# referenceStart2 = The start position of the alignment in the second row 
# lastCigar = The last cigar string that was combined with the overall cigar 
string, before it was combined 
 
def calculate_new_cigar_string(firstCigar, referenceLength1, referenceStart1, 
secondCigar, gapLength, 
                        referenceStart2, lastCigar = ""): 
   # Find all numbers associated with H in the 3 CIGAR strings. 
   firstCigarHList = re.findall(r'(\d+)H', firstCigar) 
   secondCigarHList = re.findall(r'(\d+)H', secondCigar) 
   lastCigarHList = re.findall(r'(\d+)H', lastCigar) 
 
   # Check if cigar2 is inside cigar1, if so, use cigar1 
   if int(secondCigarHList[0]) > (int(lastCigarHList[0])) and 
int(firstCigarHList[1]) < int(secondCigarHList[1]): 
      return firstCigar 
 
   # a = The gap left until the next reference starts.  
   # Calculated by taking the Reference (Exon/Intron) length (from file) MINUS 
the start position of alignment1 
   # MINUS 1. Gives the number of bases left for the read to align to. The 
matches and deletions tell how far into the  
   # reference the alignment goes. 
   a = int(referenceLength1) - (int(referenceStart1) - 1) - 
count_matches(lastCigar) - count_deletions(lastCigar) 
 
   # b = The gap between the beginning of the second reference and where the 
alignment starts. 
   # Calculated by taking the gapLength and ADDING the start position of 
alignment2 MINUS 1 
   b = gapLength + int(referenceStart2) - 1 
 
   # totalGap = The total gap (deletions) 
   totalGap = a + b 
 
   # Decide whether it is an insertion or deletion between the two reference 
alignments (will usually be a deletion). 
   newCigarValue = "" 
   if totalGap > 0: 
      newCigarValue = str(totalGap) + "D" 
   elif totalGap < 0: 
      newCigarValue = str(abs(totalGap)) + "I" 
 
   # Construct the new cigar string out of the first string and the second 
string, with the newCigarValue inbetween. 
   # Also the last H from the first string and the first H from the second string 
are removed 
   return firstCigar[:-(len(firstCigarHList[1]) + 1)] + newCigarValue + 
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secondCigar[len(secondCigarHList[0]) + 1:] 
 
 
# Takes all the rows for a read and combines the cigar strings into a single 
cigar string 
def construct_new_cigar_string(rows, refs, references): 
   cigarString = "" 
 
   for i in range(0, len(rows) - 1): 
      # The length of the gap from the previous aligned reference end to the 
current aligned reference start. 
      gapLength = calculate_length(references, refs[rows[i + 1][2]][1], 
refs[rows[i][2]][1] + 1) 
      if i == 0: 
         cigarString = calculate_new_cigar_string(rows[i][5], 
refs[rows[i][2]][0], rows[i][3], rows[i + 1][5], 
                                        gapLength, rows[i + 1][3], rows[i][5]) 
      else: 
         cigarString = calculate_new_cigar_string(cigarString, 
refs[rows[i][2]][0], rows[i][3], rows[i + 1][5], 
                                        gapLength, rows[i + 1][3], rows[i][5]) 
   # If there is only 1 row in the read, add the only rows cigar string to the 
cigar string 
   if cigarString == "": 
      cigarString = rows[0][5] 
   return cigarString 
 
# Add in 0H for the beginnings and ends that don't have a number so the program 
doesn't break 
def add_zero_Hs(line): 
   indexs = [m.start() for m in re.finditer('H', line[5])] 
   if line[5].find("H") == -1 or indexs[-1] != len(line[5]) - 1: 
      line[5] += "0H" 
   if line[5].find("H") == len(line[5]) - 1: 
      line[5] = "0H" + line[5] 
   return line 
 
# Main function that starts the program 
if __name__ == "__main__": 
 
   # SAM file BLAT output file to be read and combined 
   filename = "over6k.sam" 
   with open(filename) as file: 
      reader = csv.reader(file, delimiter = '\t') 
      # Convert the tab delimited data into a list of lists 
      data = list(reader) 
      file.close() 
 
   # Get the references from the reference file 
   references = get_references() 
   # Generate a dictionary of the references 
   dictionary = generate_reference_dict(references) 
   # Create a template row for the output 
   template = data[0] 
   # While Loop Variable 
   endReached = False 
   # Original length of the SAM file data 
   length = len(data) 
   # Open the output file 
   thefile = open('Output-' + filename, 'w') 
   while not endReached: 
      # Get the first read number 
      readNum = data[0][0] 
      # Find all the rows for the read number 
      rows, data = find_all_rows(readNum, data) 
      # Sort the rows into the correct order 




      # Find out which is the dominant read direction of the read 
      zero = 0 
      sixteen = 0 
      for line in output: 
         if line[1] == "0": 
            zero += 1 
         if line[1] == "16": 
            sixteen += 1 
 
 
      readOrder = "0" if zero > sixteen else "16" 
      i = 0 
      while i < len(output) - 1: 
         # Add 0H's to the rows cigar strings if necessary 
         output[i] = add_zero_Hs(output[i]) 
         output[i + 1] = add_zero_Hs(output[i + 1]) 
 
         # If the read order is not the dominant direction then delete the row 
         if output[i][1] != readOrder: 
            del output[i] 
            i -= 1 
         # If the rows have the same reference name 
         elif output[i][2] == output[i + 1][2]: 
            # Return whichever row has the most matches 
            if count_matches(output[i][5]) >= count_matches(output[i + 1][5]): 
               newLine = output[i] 
            else: 
               newLine = output[i + 1] 
            output[i] = newLine 
            # Delete the unused line from the output 
            del output[i + 1] 
            i -= 1 
         i += 1 
 
      # Calculate the gapLength to the first reference in the output 
      startNum = calculate_length(references, dictionary[output[0][2]][1]) + 
int(output[0][3]) 
      # Calculate the new overall cigar string for the entire read 
      newCigarString = construct_new_cigar_string(output, dictionary, references) 
      # Change the template to have the correct information for the read 
      template[0] = output[0][0] 
      template[1] = output[0][1] 
      template[2] = "BRCARD1_geneseq" 
      template[3] = str(startNum) 
      template[5] = newCigarString 
      # Write the line to the output file 
      thefile.write("\t".join(template) + "\n") 
 
      # Once the list of SAM BLAT data is empty exit the while loop and close the 
output file 
      if len(data) == 0: 
         endReached = True 





Appendix E: BRCA1 Long Range PCR variations 
 
 
Figure E Part 1: Varying long range BRCA1 PCR results.  




Figure E Part 2: Varying long range BRCA1 PCR results.  
Samples that underwent MinION sequencing in Sample 1 or Sample 2 are indicated. Size in bp of relevant bands in the 
marker lane (Ladder) is indicated on each figure. 2µl of each reaction was run on 1% agarose gels. A: Touchdown 
protocol based on the alternative PCR for full length BRCA1. Annealing temperature started at 66°C and finished at 
59°C. B: Standard PCR for full length BRCA1 protocol and alternative PCR protocol comparison, with MPW controls for 
each. C: Standard PCR for full length BRCA1. D: Multiple replicates of the standard PCR for full length BRCA1 performed 
at the same time. E: Temperature gradient based on the standard protocol for full length BRCA1. Annealing 
temperature is displayed for each sample. F and G: Standard PCR for full length BRCA1 multiple replicates performed 
at the same time 
